<SEC-DOCUMENT>0000947871-20-000452.txt : 20200513
<SEC-HEADER>0000947871-20-000452.hdr.sgml : 20200513
<ACCEPTANCE-DATETIME>20200513084911
ACCESSION NUMBER:		0000947871-20-000452
CONFORMED SUBMISSION TYPE:	424B2
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20200513
DATE AS OF CHANGE:		20200513

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			QUEST DIAGNOSTICS INC
		CENTRAL INDEX KEY:			0001022079
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				161387862
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B2
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-232138
		FILM NUMBER:		20871190

	BUSINESS ADDRESS:	
		STREET 1:		500 PLAZA DRIVE
		CITY:			SECAUCUS
		STATE:			NJ
		ZIP:			07094
		BUSINESS PHONE:		9735202700

	MAIL ADDRESS:	
		STREET 1:		500 PLAZA DRIVE
		CITY:			SECAUCUS
		STATE:			NJ
		ZIP:			07094

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CORNING CLINICAL LABORATORIES INC
		DATE OF NAME CHANGE:	19960903
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B2
<SEQUENCE>1
<FILENAME>ss173475_424b2.htm
<DESCRIPTION>PROSPECTUS SUPPLEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>Calculation of the
Registration Fee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>&nbsp;&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-top: black 1.5pt solid; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1.2pt"><B>Title of Each Class<BR>
of Securities Offered</B></TD>
    <TD STYLE="border-top: black 1.5pt solid; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1.2pt">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="border-top: black 1.5pt solid; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1.2pt; text-align: center"><B>Maximum Aggregate<BR>
Offering Price</B></TD>
    <TD STYLE="border-top: black 1.5pt solid; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1.2pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-top: black 1.5pt solid; border-bottom: black 1.5pt solid; padding: 1.2pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Amount of</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Registration Fee<FONT STYLE="font-size: 7pt">(1)</FONT></B></P></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 69%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1.2pt">2.800% Senior Notes due 2031</TD>
    <TD STYLE="width: 1%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1.2pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1.2pt">$</TD>
    <TD STYLE="width: 10%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1.2pt; text-align: right">549,197,000</TD>
    <TD STYLE="white-space: nowrap; width: 2%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1.2pt">&nbsp;</TD>
    <TD STYLE="width: 2%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1.2pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1.2pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1.2pt">$</TD>
    <TD STYLE="width: 10%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1.2pt; text-align: right">71,285.77</TD>
    <TD STYLE="white-space: nowrap; width: 3%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 1.2pt">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">(1)&nbsp;Pursuant to Rule 456(b), calculated
in accordance with Rule 457(r) of the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Filed Pursuant to Rule 424(b)(2)<BR>
Registration No. 333-232138</B></P>

<P STYLE="font: 10pt Verdana, Helvetica, Sans-Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><U>PROSPECTUS SUPPLEMENT</U></B><BR>
(To prospectus dated June 14, 2019)</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center">$550,000,000&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="image_001.jpg" ALT="Description: C:\Users\dy23967\Desktop\Quest-logo[2].jpg" STYLE="height: 115px; width: 241px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 14pt">Quest Diagnostics
Incorporated</FONT><B><BR>
</B>$550,000,000 2.800% Senior Notes due&nbsp;2031&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-indent: 0.5in">We are offering $550,000,000
aggregate principal amount of 2.800% senior notes due 2031 (the &ldquo;notes&rdquo;). The notes will mature on June 30, 2031.
We will pay interest on the notes semiannually on June 30 and December 30 of each&nbsp;year, beginning December
30, 2020. We may redeem some or all of the notes at any time at the
applicable redemption prices described in this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-indent: 0.5in">The notes will be senior unsecured obligations
of ours and will rank equally with our other existing and future senior unsecured obligations. The notes will be issued only in
registered form in minimum denominations of $2,000 and integral multiples of $1,000 in excess thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-indent: 0.5in"><B>Investing in the notes involves risks
that are described in the &ldquo;Risk Factors&rdquo; section of our Annual Report on Form&nbsp;10-K for the&nbsp;year ended December&nbsp;31,
2019 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, which are incorporated by reference into this prospectus
supplement, and in the &ldquo;Risk Factors&rdquo; section beginning on page&nbsp;S-11 of this prospectus supplement.</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 74%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 13%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Per Note</B></P></TD>
    <TD STYLE="width: 13%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Total</B></P></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Public offering price<SUP>(1)</SUP>&#9;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">99.854%</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">$549,197,000</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Underwriting discount&#9;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">0.650%</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">$&#9; &nbsp; &nbsp;3,575,000</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Proceeds, before expenses, to us&#9;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;99.204%</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">$545,622,000</TD></TR>
</TABLE>
<P STYLE="font: 3pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 3pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 3pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 3pt Times New Roman, Times, Serif; margin: 0"></P>



<P STYLE="font: 1pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><SUP>(1)</SUP></TD><TD>Plus accrued interest from May 13, 2020, if settlement occurs after
                                                                       that date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><B>Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-indent: 0.5in">The notes will be ready for delivery
in book-entry form only through the facilities of The Depository Trust Company for the accounts of its participants,
including Euroclear Bank S.A./N.V., as operator of the Euroclear System, and Clearstream Banking, soci&eacute;t&eacute;
anonyme, on or about May 13, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><I></I></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 40%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><I>Joint Book-Running Managers</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><B>Goldman Sachs &amp; Co. LLC</B></TD>
    <TD STYLE="width: 32%; padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><B>J.P. Morgan </B></TD>
    <TD STYLE="width: 35%; padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><B>Mizuho Securities</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><B>Morgan Stanley</B></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><B>Wells Fargo Securities</B></TD></TR>
</TABLE>
<P STYLE="font: 6pt Times New Roman, Times, Serif; margin: 0">&nbsp;&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><I>Co-Managers</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 9pt"><B>Credit Agricole CIB</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 9pt"><B>MUFG</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 9pt"><B>Fifth Third Securities</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 9pt"><B>PNC Capital Markets LLC</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 9pt"><B>BNY Mellon Capital Markets, LLC</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 9pt"><B>BofA Securities </B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-bottom: 3pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 9pt"><B>KeyBanc Capital Markets</B></FONT></TD></TR>
<TR>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 21%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 25%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 6pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>



<P STYLE="font: 6pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 40%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">The date of this prospectus supplement is
May 11, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">Page</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Prospectus Supplement</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; padding-right: 0.3in"><A HREF="#Summary">SUMMARY</A></TD>
    <TD STYLE="width: 12%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">S-2</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.3in"><A HREF="#RiskFactors">RISK FACTORS</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">S-11</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.5in; padding-right: 0.3in; text-indent: -0.5in"><A HREF="#CautionaryStatement">CAUTIONARY STATEMENT FOR PURPOSES OF THE &ldquo;SAFE HARBOR&rdquo; PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">S-13</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.3in"><A HREF="#UseofProceeds">USE OF PROCEEDS</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">S-16</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.3in"><A HREF="#Capitalization">CAPITALIZATION</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">S-17</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.3in"><A HREF="#DescriptionofNotes">DESCRIPTION OF NOTES</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">S-18</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.3in"><A HREF="#UnitedStatesFederal">UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">S-37</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.3in"><A HREF="#Underwriting">UNDERWRITING (CONFLICTS OF INTEREST)</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">S-42</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.3in"><A HREF="#LegalMatters">LEGAL MATTERS</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">S-46</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.3in"><A HREF="#Experts">EXPERTS</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">S-46</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.3in"><A HREF="#WhereYouCanFind">WHERE YOU CAN FIND MORE INFORMATION</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">S-46</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><B>Prospectus</B></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.3in"><A HREF="#AboutThisProspectus2">ABOUT THIS PROSPECTUS</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">ii</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.3in"><A HREF="#WhereYouCanFind2">WHERE YOU CAN FIND MORE INFORMATION</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">1</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.5in; padding-right: 0.3in; text-indent: -0.5in"><A HREF="#CautionaryStatement2">CAUTIONARY STATEMENT FOR PURPOSES OF THE &ldquo;SAFE HARBOR&rdquo; PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">2</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.3in"><A HREF="#ProspectusSummary2">PROSPECTUS SUMMARY</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">5</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.3in"><A HREF="#RiskFactors2">RISK FACTORS</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">6</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.3in"><A HREF="#UseofProceeds2">USE OF PROCEEDS</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">7</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.3in"><A HREF="#SecuritiesWeMayIssue">SECURITIES WE MAY ISSUE</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.3in"><A HREF="#DescriptionofSenior2">DESCRIPTION OF SENIOR DEBT SECURITIES</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">9</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.3in"><A HREF="#PlanofDistribution2">PLAN OF DISTRIBUTION</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">10</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.3in"><A HREF="#Validity2">VALIDITY OF THE SECURITIES</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">11</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.3in"><A HREF="#Experts2">EXPERTS</A></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">11</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 12pt; margin-right: 0; margin-left: 0; text-indent: 0.5in">&nbsp;Neither
we nor the underwriters have authorized anyone&nbsp;to provide you with any information or to make any representation not contained
in or incorporated by reference into this prospectus supplement or the accompanying prospectus or included in any free writing
prospectus that we may file with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) in connection with this offering.
Neither we nor the underwriters take any responsibility for, or can provide any assurances as to, the reliability of any information
that others may provide you. Neither we nor the underwriters are making an offer to sell these securities in any jurisdiction
where the offer or sale is not permitted. You should assume that the information appearing in this prospectus supplement, the
accompanying prospectus and the documents incorporated by reference is accurate only as of their respective dates. Our business,
financial condition, cash flows, results of operations and prospects may have changed since these dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">References to &ldquo;we,&rdquo; &ldquo;us,&rdquo;
&ldquo;our,&rdquo; &ldquo;Quest Diagnostics&rdquo; and the &ldquo;Company&rdquo; are to Quest Diagnostics Incorporated and its
consolidated subsidiaries or, as the context may require, Quest Diagnostics Incorporated only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid; width: 1%">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; width: 98%">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-top: Black 1pt solid; width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 12pt"><B><A NAME="Summary" TITLE="Summary"></A>SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><I>This summary highlights selected information
appearing elsewhere in this prospectus supplement and the documents incorporated herein and may not contain all of the information
that is important to you. You should carefully read this prospectus supplement and the accompanying prospectus in their entirety,
including the documents incorporated by reference.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Our Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Quest Diagnostics empowers people to
take action to improve health outcomes. We use our extensive database of clinical lab results to derive diagnostic insights that
reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Our diagnostic information
services business (&ldquo;DIS&rdquo;) provides information and insights based on the industry-leading menu of routine, non-routine
and advanced clinical testing and anatomic pathology testing, and other diagnostic information services. We provide services to
a broad range of customers, including patients, clinicians, hospitals, independent delivery networks, health plans, employers and
accountable care organizations. We offer the broadest access in the United States to diagnostic information services through our
nationwide network of laboratories, patient service centers and phlebotomists in physician offices and our connectivity resources,
including call centers and mobile paramedics, nurses and other health and wellness professionals. We are the world&rsquo;s leading
provider of diagnostic information services. We provide interpretive consultation with one of the largest medical and scientific
staffs in the industry. Our DIS business accounted for greater than 95% of net revenues in 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">In our Diagnostic Solutions (&ldquo;DS&rdquo;)
businesses, which account for the balance of our consolidated net revenues, we offer a variety of solutions for life insurers and
healthcare organizations and clinicians. We are the leading provider of risk assessment services for the life insurance industry.
In addition, we offer healthcare organizations and clinicians robust information technology solutions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">During 2019, we generated net revenues
of $7.7&nbsp;billion and processed approximately 175 million test requisitions through our extensive laboratory network.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Our principal executive offices are located
at 500 Plaza Drive, Secaucus, New Jersey 07094, telephone&nbsp;number: (973) 520-2700.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">A novel strain of coronavirus (&ldquo;COVID-19&rdquo;)
continues to spread and severely impact the economy of the United States and other countries around the world. During January and
February 2020, we experienced growth in our organic testing volume compared to the prior year period. However, in March 2020, we
experienced, and anticipate that we will continue to experience, a material decline in testing volumes due to the COVID-19 pandemic.
Federal, state and local governmental policies and initiatives designed to reduce the transmission of COVID-19 have resulted in,
among other things, a significant reduction in physician office visits, the cancellation of elective medical procedures, customers
closing or severely curtailing their operations (voluntarily or in response to government orders), and the adoption of work-from-home
or shelter-in-place policies, all of which have had, and we believe will likely continue to have, an adverse impact on our consolidated
results of operations, financial position, and cash flows. As a result, operating results for the three months ended March 31,
2020 may not be indicative of the results that may be expected for the remainder of the year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">For a discussion of the impact of COVID-19
on our business, operations and financial condition, including the risks associated with COVID-19, please see our Quarterly Report
on Form 10-Q for the quarter ended March 31, 2020, which is incorporated by reference herein.</P>

</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-top: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-top: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-top: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>The Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The following is a brief summary of some
of the terms of this offering. For a more complete description of the terms of the notes, see &ldquo;Description of Notes&rdquo;
in this prospectus supplement and &ldquo;Description of Senior Debt Securities&rdquo; in the accompanying prospectus.&#9;</P>

</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 47%; padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><B>Issuer</B></TD>
    <TD STYLE="width: 51%; padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">Quest Diagnostics Incorporated.</TD>
    <TD STYLE="border-right: Black 1pt solid; width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><B>Notes Offered</B></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">$550,000,000&nbsp;aggregate principal amount of
    2.800% senior notes due 2031.</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><B>Maturity</B></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">June 30, 2031.</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"><B>Interest Payment Dates</B></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">June
    30 and December 30,
    beginning December 30, 2020.</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><B>Ranking</B></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">The notes will be senior unsecured obligations of Quest Diagnostics
        and will rank equally with Quest Diagnostics&rsquo; other existing and future senior unsecured obligations. The notes will be effectively
        subordinated to any existing and future secured obligations of Quest Diagnostics as to the assets securing such obligations.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">In addition, the notes will be structurally subordinated
        to any existing and future indebtedness and other obligations of Quest Diagnostics&rsquo; subsidiaries. Quest Diagnostics&rsquo;
        subsidiaries are not guarantors of the notes. To the extent the indenture governing Quest Diagnostics&rsquo; existing debt securities
        requires any domestic subsidiary of Quest Diagnostics to guarantee Quest Diagnostics&rsquo; existing debt securities issued under
        the indenture, any such subsidiary will be required to guarantee the notes in a substantially consistent manner for so long as
        such subsidiary guarantees such existing debt securities.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">As of March 31, 2020, after giving effect to this offering(as
        if the foregoing had occurred on that date):</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 20.9pt; text-indent: -20.9pt"><FONT STYLE="font-family: Symbol">&#183;&#9;</FONT>
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Quest Diagnostics would have had debt outstanding of $4,580 million, of which $33 million is secured; and</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 20.9pt; text-indent: -20.9pt"><FONT STYLE="font-family: Symbol">&#183;&#9;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;our
        subsidiaries would have had debt outstanding of $32 million, all of which was secured.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">For more information, see &ldquo;Description of Notes&rdquo;
        &ldquo;Use of Proceeds&rdquo; and &ldquo;Capitalization.&rdquo;</P></TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><B>Optional Redemption</B></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Prior to March
                                                          30, 2031&nbsp;(three months prior to their
                                                          maturity date, the &ldquo;par call date&rdquo;), we may redeem the notes, as a whole at any time or in part from time to</P></TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD></TR></TABLE>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-top: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-top: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; width: 1%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; width: 47%">&nbsp;&nbsp;&nbsp;&nbsp;<B></B></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; width: 51%"> </P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">time, at our option, at a redemption price equal to the greater of:</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 20.9pt; text-indent: -20.9pt"><FONT STYLE="font-family: Symbol">&#183;&#9;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;100%
of the principal amount of the notes to be redeemed, and</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 20.9pt; text-indent: -20.9pt"><FONT STYLE="font-family: Symbol">&#183;&#9;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the
        sum of the present values of the Remaining Scheduled Payments (as defined in this prospectus supplement) discounted, on a semiannual
        basis, assuming a 360-day&nbsp;year consisting of twelve 30-day&nbsp;months, at the Treasury Rate (as defined in this prospectus
        supplement) plus 35 basis points,</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">plus accrued interest to, but excluding, the date of redemption,
        which has not been paid.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">On or after the&nbsp;par call date, we may redeem the notes,
        as a whole at any time or in part from time to time, at our option, at a redemption price equal to 100% of the principal amount
        of the notes being redeemed plus accrued interest to, but excluding, the date of redemption, which has not been paid.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">For a more detailed description, see &ldquo;Description of
        Notes&mdash;Optional Redemption.&rdquo;</P></TD>
    <TD STYLE="border-right: Black 1pt solid; width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><B>Repurchase Upon a Change of Control</B></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">Upon the occurrence of a Change of Control Triggering Event (as defined in this prospectus supplement), we will be required to make an offer to purchase the notes at a price equal to 101% of their principal amount plus accrued and unpaid interest to, but excluding, the date of repurchase.&nbsp;&nbsp;See &ldquo;Description of Notes&mdash;Change of Control.&rdquo;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><B>Covenants</B></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">The indenture governing the notes will contain covenants
        that, among other things, will limit our ability and/or the ability of certain of our subsidiaries to:</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 20.9pt; text-indent: -20.9pt"><FONT STYLE="font-family: Symbol">&#183;&#9;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;create
        certain liens;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 20.9pt; text-indent: -20.9pt"><FONT STYLE="font-family: Symbol">&#183;&#9;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;enter
        into certain sale and leaseback transactions;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 20.9pt; text-indent: -20.9pt"><FONT STYLE="font-family: Symbol">&#183;&#9;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;consolidate,
        merge or transfer all or substantially all of our assets; and</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 20.9pt; text-indent: -20.9pt"><FONT STYLE="font-family: Symbol">&#183;&#9;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;incur
        indebtedness at non-guarantor subsidiaries.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">These covenants are subject to important exceptions and qualifications,
        which are described in this prospectus supplement. For a more detailed description, see &ldquo;Description of Notes.&rdquo;</P></TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><B>Use of Proceeds</B></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">We estimate that the net proceeds from this offering of notes after deducting underwriting discounts but before deducting other expenses of the offering will </TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD></TR></TABLE>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-top: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-top: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; width: 1%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; width: 47%"><B></B></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt; width: 51%">be approximately $545,622,000.&nbsp;&nbsp;We expect to use the net proceeds from this offering for general corporate purposes, which may include the redemption orrepayment of indebtedness.&nbsp; The indebtedness we may redeem or repay with the net proceeds of this offering includes our $550 million aggregate principal amount of 4.70% Senior Notes due 2021 (the &ldquo;4.70% Senior Notes&rdquo;) and outstanding borrowings under our senior unsecured revolving credit facility and our secured receivables credit facility. &nbsp;See &ldquo;Use of Proceeds.&rdquo;&nbsp;&nbsp;This prospectus supplement is not a notice of redemption.&nbsp;&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><B>Conflicts of Interest</B></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">As described in &ldquo;Use of Proceeds,&rdquo; the net proceeds of this offering may be used for general corporate purposes, which may include the redemption or repayment of indebtedness, including our 4.70% Senior Notes pursuant to the applicable provisions of the indenture governing these notes and our outstanding borrowings under our senior unsecured revolving credit facility and our secured receivables credit facility. &nbsp;Certain of the underwriters (or their affiliates) may hold and would receive a portion of the proceeds from this offering if such notes were to be redeemed or repaid. &nbsp;In addition, certain of the underwriters (or their affiliates) may be lenders under our senior unsecured revolving credit facility or our secured receivables credit facility and would receive a portion of the proceeds from this offering if outstanding borrowings under such credit facilities were to be repaid.&nbsp;&nbsp;If any one underwriter, together with its affiliates, were to receive 5% or more of the net proceeds of this offering by reason of the redemption or repayment, such underwriters would be deemed to have a &ldquo;conflict of interest&rdquo; within the meaning of Rule 5121 of the Financial Industry Regulatory Authority, Inc. (&ldquo;Rule 5121&rdquo;). &nbsp;Accordingly, this offering will be conducted in accordance with Rule 5121. &nbsp;No underwriter with a &ldquo;conflict of interest&rdquo; under Rule 5121 will confirm sales to any account over which it exercises discretion without the specific written approval of the account holder.</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><B>Risk Factors</B></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">See &ldquo;Risk Factors&rdquo; and the other information in this prospectus supplement and in our Annual Report on Form&nbsp;10-K for the fiscal&nbsp;year ended December&nbsp;31, 2019 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, which are incorporated by reference into this prospectus supplement, for a discussion of factors you should carefully consider before deciding to invest in the notes.</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><B>Governing Law</B></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">The indenture and the notes will be governed by, and construed in accordance with, the laws of the State of </TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"></TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">New York without application of principles of conflicts of law thereunder.</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; width: 1%">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; width: 47%"><B>Trustee</B></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt; width: 51%">The Bank of New York Mellon.</TD>
    <TD STYLE="border-right: Black 1pt solid; width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt"></TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-left: Black 1pt solid; border-top: Black 1pt solid; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="21" STYLE="border-top: Black 1pt solid">&nbsp;</TD><TD STYLE="border-right: Black 1pt solid; border-top: Black 1pt solid; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-left: Black 1pt solid; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="21">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>Summary Financial Data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The following table presents summary
historical financial data at the dates and for each of the&nbsp;periods presented. We derived the summary historical operations
and other data for the&nbsp;years ended December 31, 2019, 2018 and 2017 and the summary historical balance sheet data at December&nbsp;31,
2019 and 2018 from our audited consolidated financial statements incorporated by reference herein. We derived the summary historical
balance sheet data at December 31, 2017 from our audited consolidated financial statements not incorporated by reference herein.
We derived the summary historical financial data as of and for the three months ended March 31, 2020 and 2019 from our unaudited
interim consolidated financial statements and related notes incorporated by reference herein, except for the summary historical
balance sheet data at March 31, 2019, which is derived from our unaudited interim consolidated financial statements included in
our Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, which is not incorporated by reference herein. The summary
historical financial data as of and for the three months ended March 31, 2020 and 2019 reflects all adjustments that, in our opinion,
are necessary for a fair statement of the financial condition and results of operations at and for the periods presented. Due to
the impact of COVID-19, operating results for interim periods are not necessarily indicative of the results that may be expected
for the full year. See &ldquo;&mdash;Recent Developments&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">You should not take historical results
as necessarily indicative of the results that may be expected for any future period. The summary historical financial data presented
below is only a summary and should be read together with our audited consolidated financial statements and related notes and management&rsquo;s
discussion and analysis of financial condition and results of operations included in our Annual Report on Form&nbsp;10-K for the&nbsp;year
ended December&nbsp;31, 2019 and our unaudited interim consolidated financial statements and related notes and management&rsquo;s
discussion and analysis of financial condition and results of operations included in our Quarterly Report on Form 10-Q for the
quarter ended March 31, 2020, each of which is incorporated by reference into this prospectus supplement.</P>

</TD><TD STYLE="border-right: Black 1pt solid; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-left: Black 1pt solid; padding-bottom: 1pt">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended December&nbsp;31,</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</TD><TD STYLE="border-right: Black 1pt solid; padding-bottom: 1pt">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-left: Black 1pt solid; padding-bottom: 1pt">&nbsp;</TD>
    <TD>(dollars in millions)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="border-right: Black 1pt solid; padding-bottom: 1pt">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-left: Black 1pt solid; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Operations Data:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(a) (b) (c)</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(a) (d) (e)</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(a) (f) (g)</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(a) (h) (i)</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(a) (b) (j)</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-left: Black 1pt solid; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 48%; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Net revenues&#9;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">7,726</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">7,531</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">7,402</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">1,822</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 7%; text-align: right">1,891</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="border-right: Black 1pt solid; width: 1%">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Operating income&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,231</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,101</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,165</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">175</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">248</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Income from continuing operations&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">886</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">788</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">824</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">106</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">176</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-left: Black 1pt solid; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 8.65pt">Income from discontinued operations, net of tax &#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">20</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-right: Black 1pt solid; padding-bottom: 1pt">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Net income&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">906</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">788</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">824</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">106</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">176</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-left: Black 1pt solid; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 8.65pt">Less:&nbsp;&nbsp;Net income attributable to noncontrolling interests&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">48</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">52</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">52</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">7</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">12</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-right: Black 1pt solid; padding-bottom: 1pt">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-left: Black 1pt solid; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 8.65pt">Net income attributable to Quest Diagnostics&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">858</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">736</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">772</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">99</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">164</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-right: Black 1pt solid; padding-bottom: 1pt">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-left: Black 1pt solid; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Amounts attributable to Quest Diagnostics&rsquo; shareholders:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Income from continuing operations&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">838</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">736</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">772</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">99</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">164</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-left: Black 1pt solid; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 8.65pt">Income from discontinued operations, net of tax&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">20</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-right: Black 1pt solid; padding-bottom: 1pt">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-left: Black 1pt solid; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: -8.65pt; padding-left: 8.65pt">Net income&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">858</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">736</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">772</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">99</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">164</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-right: Black 1pt solid; padding-bottom: 1pt">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-left: Black 1pt solid; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Balance Sheet Data:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-indent: -8.65pt; padding-left: 8.65pt">(at end of&nbsp;period):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Cash and cash equivalents&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,192</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">135</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">137</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">342</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">464</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Total assets&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,843</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,003</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,503</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,049</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,937</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Long-term debt&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,966</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,429</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,748</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,033</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,131</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
<TR STYLE="border-bottom: Black 1pt solid; vertical-align: bottom; background-color: White">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Total debt&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,770</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,893</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,784</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,036</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,239</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="border-right: Black 1pt solid">&nbsp;</TD>
    </TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>




<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="border-top: Black 1pt solid; vertical-align: bottom">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="11" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Year Ended December&nbsp;31,</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD>(dollars in millions)</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2017</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2020</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-left: Black 1pt solid; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt; width: 48%">Redeemable noncontrolling interest&#9;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 7%">76</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 7%">77</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 7%">80</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 7%">76</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 7%">77</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Other Data:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Net cash provided by operating activities&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,243</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,200</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,175</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">247</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">275</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Net cash used in investing activities&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(411</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(801</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(830</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(206</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(110</TD><TD STYLE="text-align: left">)</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Net cash provided by (used in) financing activities&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">225</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(401</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(592</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(891</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">164</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Capital expenditures&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">400</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">383</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">252</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">83</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">47</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Purchases of treasury stock&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">353</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">322</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">465</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">53</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="text-align: left; text-indent: -8.65pt; padding-left: 8.65pt">Dividends paid&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">286</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">266</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">247</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">72</TD><TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>





<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="vertical-align: bottom; padding-top: 3pt; text-align: left"><!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 8pt">(a)</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">On January 1, 2019, we adopted a new lease accounting standard, which required
    us to recognize an asset and a liability for most operating leases on our balance sheet. Operating lease right-of-use assets
    were $518 million, $512 million and $497 million as of December 31, 2019, March 31, 2020, and March 31, 2019, respectively.
    Operating lease liabilities were $558 million, $554 million and $538 million as of December 31, 2019, March 31, 2020 and March
    31, 2019, respectively. Prior periods have not been restated. During the third quarter of 2006, we completed the wind down
    of Nichols Institute Diagnostics (&ldquo;NID&rdquo;), a test kit manufacturing subsidiary, which was reported as a discontinued
    operation for all periods presented.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 90%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; width: 1%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 8pt">(b)</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">On February 11, 2019, we completed the acquisition of certain assets of the clinical
    laboratory services business of Boyce &amp; Bynum Pathology Laboratories, P.C. (&ldquo;Boyce &amp; Bynum&rdquo;). Consolidated
    operating results for 2019 include the results of operations of Boyce &amp; Bynum subsequent to the closing of the acquisition.
    For further details regarding our acquisitions, see Note 6 to the audited consolidated financial statements included in our
    Annual Report on Form 10-K for the year ended December 31, 2019.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 8pt">(c)</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">Operating income included (for 2019):&#9;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 8pt">&#183;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">pre-tax amortization expense of $96 million;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 8pt">&#183;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">pre-tax charges of $78 million, primarily associated with systems conversions and integration
    incurred in connection with further restructuring and integrating our business; and</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 8pt">&#183;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">a net pre-tax gain of $89 million, primarily due to a gain associated with the sale and leaseback
    of a property, a gain associated with the decrease in the fair value of the contingent consideration accruals associated with
    previous acquisitions, and a gain associated with an insurance claim for hurricane related losses, partially offset by costs
    incurred related to a data security incident and non-cash asset impairment charges.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">In addition to the items included in operating income, income from continuing
    operations included:</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 8pt">&#183;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">pre-tax amortization expense of $15 million included in equity in earnings of equity method
    investees, net of taxes; and</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 8pt">&#183;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">excess tax benefits associated with stock-based compensation arrangements of $13 million.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">Discontinued operations, net of taxes, for the year ended December 31, 2019 includes
    discrete tax benefits of $20 million associated with the favorable resolution of certain tax contingencies related to NID.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">In December 2019, we completed a senior notes offering, consisting of $800 million
    aggregate principal amount of 2.95% senior notes due June 2030 (the &ldquo;2030 Senior Notes&rdquo;), which were issued at
    an original issue discount of $2 million. During January 2020, the net proceeds from the 2030 Senior Notes, along with cash
    on hand, were used to redeem in full our senior notes due January 2020 and our senior notes due March 2020.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 8pt">(d)</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">On February 1, 2018, we completed the acquisition of Mobile Medical Examination
    Services, LLC. (&ldquo;MedXM&rdquo;). On June 18, 2018, we completed the acquisition of the outreach laboratory services business
    of Cape Cod Healthcare, Inc. On September 19, 2018, we completed the acquisition of ReproSource, Inc. (&ldquo;ReproSource&rdquo;).
    On November 6, 2018, we completed the acquisition of the U.S. laboratory services business of Oxford Immunotec, Inc. (&ldquo;Oxford&rdquo;).
    Consolidated operating results for 2018 include the results of operations of MedXM, the outreach laboratory services business
    of Cape Cod Healthcare, Inc., ReproSource and Oxford subsequent to the closing of the applicable acquisition. For further
    details regarding our acquisitions, see Note 6 to the audited consolidated financial statements included in our Annual Report
    on Form 10-K for the year ended December 31, 2019.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 8pt">(e)</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">Operating income included (for 2018):&#9;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 8pt">&#183;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">pre-tax charges of $122 million, primarily associated with workforce reductions, systems
    conversions and integration incurred in connection with further restructuring and integrating our business;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 8pt">&#183;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">pre-tax amortization expense of $90 million; and</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid; border-top: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-top: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid; width: 1%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 8pt">&#183;</FONT></TD>
    <TD STYLE="width: 90%"></FONT> <FONT STYLE="font-size: 8pt">pre-tax charges of $2 million, primarily associated with costs incurred related to certain legal matters and a loss on the sale of a foreign subsidiary, partially offset by a gain associated with the decrease in the fair value of the contingent consideration accrual associated with a previous acquisition and an insurance claim for hurricane related losses.</TD>
    <TD STYLE="border-right: Black 1pt solid; width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">In addition to the items included in operating income, income from continuing
    operations included:</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 8pt">&#183;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">pre-tax amortization expense of $17 million included in equity in earnings of equity method
    investees, net of taxes;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 8pt">&#183;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">excess tax benefits associated with stock-based compensation arrangements of $18 million;
    and</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 8pt">&#183;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">an income tax benefit of $14 million primarily associated with a change in a tax return accounting
    method that enabled us to accelerate the deduction of certain expenses on our 2017 tax return at the federal corporate statutory
    income tax rate in effect during 2017, partially offset by an income tax expense associated with finalizing the impact of
    the enactment of the Tax Cuts and Jobs Act (&#8220;TCJA&#8221;).</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">Pursuant to the TCJA, among other changes to U.S. corporate income tax laws,
    the federal corporate statutory income tax rate was reduced from 35% to 21% effective for 2018.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">(f)</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">On May 1, 2017, we completed the acquisition of the outreach laboratory services
    business of PeaceHealth Laboratories (&ldquo;PHL&rdquo;). On July 14, 2017, we completed the acquisition of Med Fusion, LLC
    and Clearpoint Diagnostic Laboratories, LLC (&ldquo;Med Fusion&rdquo;). On September 28, 2017, we completed the acquisition
    of the outreach laboratory services businesses of two hospitals of Hartford HealthCare Corporation (&ldquo;HHC&rdquo;), The
    William W. Backus Hospital and The Hospital of Central Connecticut. On December 1, 2017, we completed the acquisition of Cleveland
    HeartLab, Inc. (&ldquo;CHL&rdquo;). On December 7, 2017, we completed the acquisition of certain assets of the clinical and
    anatomic pathology laboratory business of Shiel Holdings, LLC (&ldquo;Shiel&rdquo;). Consolidated operating results for 2017
    include the results of operations of PHL, Med Fusion, the outreach laboratory services businesses of The William W. Backus
    Hospital and The Hospital of Central Connecticut, CHL and Shiel subsequent to the closing of the applicable acquisition. For
    further details regarding our acquisitions, see Note 6 to the audited consolidated financial statements included in our Annual
    Report on Form 10-K for the year ended December 31, 2019.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">(g)</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">Operating income included (for 2017):&#9;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 8pt">&#183;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">pre-tax charges of $105 million, primarily associated with systems conversions, integration
    and workforce reductions incurred in connection with further restructuring and integrating our business;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 8pt">&#183;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">pre-tax amortization expense of $74 million; and</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 8pt">&#183;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">pre-tax charges of $12 million, primarily a result of non-cash asset impairment charges,
    incremental costs incurred as a result of hurricanes and costs incurred related to certain legal matters.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">In addition to the items included in operating income, income from continuing
    operations included:</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 8pt">&#183;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">pre-tax amortization expense of $16 million included in equity in earnings of equity method
    investees, net of taxes;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 8pt">&#183;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">a net pre-tax gain of $2 million, primarily a result of a gain on the sale of an interest
    in an equity method investment, partially offset by non-cash asset impairment charges associated with an investment;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 8pt">&#183;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">$1 million of pre-tax restructuring and integration charges associated with our Q<SUP>2</SUP>
    Solutions joint venture;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 8pt">&#183;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">a provisional estimated income tax benefit of $106 million associated with the TCJA, including
    a deferred income tax benefit of $115 million primarily due to the remeasurement of our net deferred tax liabilities and reserves
    at the new combined federal and state income tax rate, partially offset by $9 million of current income tax expense primarily
    due to the mandatory repatriation toll charge on undistributed foreign earnings and profits;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 8pt">&#183;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">excess tax benefits associated with stock-based compensation arrangements of $37 million;
    and</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 8pt">&#183;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">income tax expense of $3 million primarily a result of recording a valuation allowance against
    certain net operating loss carryforwards in a geography impacted by hurricanes.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">Net cash provided by operating activities benefited from a decrease in tax payments
    associated with the realization of a $62 million deferred tax benefit.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">(h)</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">On January 21, 2020, we completed the acquisition of Blueprint Genetics Oy (&ldquo;Blueprint
    Genetics&rdquo;). Consolidated operating results for the three months ended March 31, 2020 included the results of operations
    of Blueprint Genetics subsequent to the closing of the acquisition. For further details regarding our acquisitions, see Note
    5 to the unaudited interim consolidated financial statements included in our Quarterly Report on Form 10-Q for the quarter
    ended March 31, 2020.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">(i)</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">Operating income included (for the three months ended March 31, 2020):&#9;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 8pt">&#183;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">pre-tax amortization expense of $25 million;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 8pt">&#183;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">pre-tax charges of $16 million, primarily associated with systems conversions and integration
    incurred in connection with further restructuring and integrating our business; and</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 8pt">&#183;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">pre-tax charges of $9 million, primarily associated with certain costs incurred as a result
    of a pandemic caused by a novel strain of coronavirus (&#8220;COVID-19&#8221;) and the resulting impact on the economy, including
    certain asset impairment charges and incremental costs incurred primarily to protect the health and safety of our employees
    and customers and to transition certain employees to a remote work environment.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">In addition to the items included in operating income, income from continuing
    operations included:</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 8pt">&#183;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">excess tax benefits associated with stock-based compensation arrangements of $8 million;
    and</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 8pt">&#183;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">pre-tax amortization expense of $3 million included in equity in earnings of equity method
    investees, net of taxes.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 8pt">(j)</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">Operating income included (for the three months ended March 31, 2019):</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 8pt">&middot;</FONT></TD>
    <TD></FONT> <FONT STYLE="font-size: 8pt">pre-tax amortization expense of $24 million;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in">&nbsp;</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in">&nbsp;</P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid; border-top: Black 1pt solid; width: 1%">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; width: 4%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; width: 4%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; width: 90%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-top: Black 1pt solid; width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 8pt">&#183;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">pre-tax charges of $22 million, primarily associated with systems conversions and integration
    incurred in connection with further restructuring and integrating our business; partially offset by</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 8pt">&#183;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">a net pre-tax gain of $8 million primarily due to a gain associated with an insurance claim
    for hurricane related losses, partially offset by non-cash asset impairment charges.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 8pt">In addition to the items included in operating income, income from continuing
    operations included:</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 8pt">&#183;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">pre-tax amortization expense of $5 million included in equity in earnings of equity method
    investees, net of taxes; and</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 8pt">&#183;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">excess tax benefits associated with stock-based compensation arrangements of $3 million.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="RiskFactors" TITLE="RiskFactors"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><I>You should carefully consider the
risks described below and in our Annual Report on Form&nbsp;10-K for the fiscal&nbsp;year ended December&nbsp;31, 2019 and our
Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, each of which is incorporated by reference into this prospectus
supplement, before making a decision to invest in our notes. The risks and uncertainties described below and in the documents incorporated
by reference are not the only ones facing our Company. Additional risks and uncertainties not presently known to us or that we
currently deem immaterial may also materially adversely affect our business and operations.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><I>If any of the matters included in
the following risks were to occur, our business, financial condition, results of operations, cash flows or prospects could be materially
adversely affected. In such case, you may lose all or part of your original investment.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Secured indebtedness incurred by Quest Diagnostics will
be effectively, and existing and future obligations of our subsidiaries (including preferred stock) will be structurally, senior
to the notes.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The notes are our senior unsecured obligations
and therefore will be effectively subordinated to our secured obligations to the extent of the value of the assets securing such
obligations. The notes will also be structurally subordinated to any existing and future indebtedness and other obligations of
our subsidiaries. Our subsidiaries are not guarantors of the notes. Certain of our domestic subsidiaries may be required to become
subsidiary guarantors of our existing debt securities issued prior to December 2019 if they incur or assume any indebtedness, subject
to exceptions set forth in the indenture governing the debt securities, or guarantee any indebtedness of our Company when the amount
of such indebtedness, together with any other outstanding indebtedness of our Company guaranteed by our subsidiaries that do not
guarantee our existing debt securities, exceeds $50&nbsp;million in the aggregate at any time. To the extent the indenture governing
the debt securities requires any domestic subsidiary of our Company to guarantee our Company&rsquo;s existing debt securities issued
under the indenture, any such subsidiary will be required to guarantee the notes offered hereby in a substantially consistent manner
for so long as such subsidiary guarantees such existing debt securities. See &ldquo;Description of Notes&mdash;Future Subsidiary
Guarantors.&rdquo; The indenture governing the notes does not limit the amount of indebtedness that we can incur, but does limit
the amount of indebtedness our subsidiaries who do not provide subsidiary guarantees are permitted to incur. In addition, the indenture
governing the notes limits the amount of secured indebtedness Quest Diagnostics and its restricted subsidiaries may incur pursuant
to the covenant described under the heading &ldquo;Description of Notes&mdash;Limitation on Liens.&rdquo; This covenant is subject
to important exceptions described under such heading. As of March 31, 2020, after giving effect to this offering (as if the foregoing
had occurred on that date), Quest Diagnostics would have had outstanding $33 million of secured debt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We conduct our operations through subsidiaries,
which generate a substantial portion of our operating income and cash flow. As a result, distributions or advances from our subsidiaries
are a major source of funds necessary to meet our debt service and other obligations. Contractual provisions, laws or regulations,
as well as any subsidiary&rsquo;s condition and operating requirements, may limit our ability to obtain cash required to pay our
debt service and other obligations. The notes will be structurally subordinated to all existing and future obligations of our subsidiaries,
including claims with respect to trade payables. As of March 31, 2020, after giving effect to this offering (as if the foregoing
had occurred on that date), our subsidiaries would have had debt outstanding of $32 million, all of which would have been secured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify"><B>If
active trading markets for the notes do not develop, you may not be able to resell them.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The notes are new issues of securities
for which there currently are no trading markets. Although the underwriters have informed us that they intend to make markets in
the notes, they are not obligated to do so, and any such market-making activities may be discontinued at any time without notice.
As a result, we cannot provide any assurances that trading markets for the notes will ever develop or be maintained. Further, we
can make no assurances as to the liquidity of any markets that may develop for the notes, your ability to sell your notes or the
prices at which you will be able to sell your notes. Future trading prices of the notes will depend on many factors, including
prevailing interest rates, our financial condition and results of operations, the condition of the industry in </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B></B></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">which
we operate generally, the then-current ratings assigned to the notes and the market for similar securities. Accordingly, you may
be required to bear the financial risk of an investment in the notes for an indefinite period of time. We do not intend to apply
for listing or quotation of the notes on any securities exchange or automated quotation system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="CautionaryStatement" TITLE="CautionaryStatement"></A></B></FONT></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="CautionaryStatement" TITLE="CautionaryStatement"></A>CAUTIONARY
STATEMENT FOR PURPOSES OF THE &ldquo;SAFE HARBOR&rdquo; PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Some statements and disclosures in this
prospectus supplement, or the accompanying prospectus and the documents incorporated herein or therein by reference, are forward-looking
statements. Forward-looking statements include our expected use of proceeds and all statements that do not relate solely to historical
or current facts and can be identified by the use of words such as &ldquo;may,&rdquo; &ldquo;believe,&rdquo; &ldquo;will,&rdquo;
&ldquo;expect,&rdquo; &ldquo;project,&rdquo; &ldquo;estimate,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;plan&rdquo; or &ldquo;continue.&rdquo;
These forward-looking statements are based on our current plans and expectations and are subject to a number of risks and uncertainties
that could cause our plans and expectations, including actual results, to differ materially from the forward-looking statements.
The Private Securities Litigation Reform Act of 1995, or the Litigation Reform Act, provides a &ldquo;safe harbor&rdquo; for forward-looking
statements to encourage companies to provide prospective information about their companies without fear of litigation. We would
like to take advantage of the &ldquo;safe harbor&rdquo; provisions of the Litigation Reform Act in connection with the forward-looking
statements included, or incorporated by reference, in this document. Investors are cautioned not to unduly rely on such forward-looking
statements when evaluating the information presented, or incorporated by reference, in this document. The following important factors
could cause our actual financial results to differ materially from those projected, forecasted or estimated by us in forward-looking
statements:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>The projected impact of COVID-19 on our business operating results, cash flows and/or financial condition and the impacts of
the measures we have taken in response to COVID-19 and the impacts on us.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>Heightened competition from commercial clinical testing companies, hospitals, physicians and others.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>Increased pricing pressure from customers, including payers and patients.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD>A decline in economic conditions.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD>Impact of changes in payment mix, including increased patient financial responsibility and any shift from fee-for-service to
discounted, capitated or bundled fee arrangements.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD>Adverse actions by government or other third-party payers, including healthcare reform that focuses on reducing healthcare
costs but does not recognize the value and importance to healthcare of clinical testing or innovative solutions, unilateral reduction
of fee schedules payable to us, unilateral recoupment of amounts allegedly owed and competitive bidding.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD>The impact upon our testing volume and collected revenue or general or administrative expenses resulting from compliance with
policies and requirements imposed by Medicare, Medicaid and other third-party payers. These include:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(1)</TD><TD>the requirements of government and other payers to provide diagnosis codes and other information for many tests;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(2)</TD><TD>inability to obtain from patients a valid advance consent form for tests that cannot be billed without prior receipt of the
form;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(3)</TD><TD>the impact of additional or expanded limited coverage policies and limits on the allowable number of test units or ordering
frequency of same; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(4)</TD><TD>the impact of increased prior authorization programs.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD>Adverse results from pending or future government investigations, lawsuits or private actions. These include, in particular,
monetary damages, loss or suspension of licenses, and/or suspension or exclusion from the Medicare and Medicaid programs and/or
criminal penalties.</TD></TR></TABLE>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD>Failure to efficiently integrate acquired businesses and to manage the costs related to any such integration, or to retain
key technical, professional or management personnel.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(j)</TD><TD>Denial, suspension or revocation of Clinical Laboratory Improvement Act (&ldquo;CLIA&rdquo;) certification or other licenses
for any of our clinical laboratories under the CLIA standards, revocation or suspension of the right to bill the Medicare and Medicaid
programs or other adverse regulatory actions by federal, state and local agencies.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(k)</TD><TD>Changes in and complexity of federal, state or local laws or regulations, including changes that result in new or increased
federal or state regulation of commercial clinical laboratories, tests developed by commercial clinical laboratories or other products
or services that we offer or activities in which we are engaged, including regulation by the U.S. Food and Drug Administration.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(l)</TD><TD>Inability to achieve expected benefits from our acquisitions of other businesses.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(m)</TD><TD>Inability to achieve additional benefits from our business performance tools and efficiency initiatives.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(n)</TD><TD>Adverse publicity and news coverage about the diagnostic information services industry or us.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(o)</TD><TD>Failure of the Company to maintain, defend and secure its financial, accounting, technology, customer data and other operational
systems from cyberattacks, information technology system outages, telecommunications failures, malicious human acts and failure
of the systems of third parties upon which the Company relies to do the same.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(p)</TD><TD>Development of technologies that substantially alter the practice of clinical testing, including technology changes that lead
to the development of more convenient or cost-effective testing, or testing to be performed outside of a commercial clinical laboratory,
such as (1) point-of-care testing that can be performed by physicians in their offices, (2) advanced testing that can be performed
by hospitals in their own laboratories or (3) home testing that can be carried out without requiring the services of clinical laboratories.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(q)</TD><TD>Negative developments regarding intellectual property and other property rights that could prevent, limit or interfere with
our ability to develop, perform or sell our tests or operate our business. These include:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(1)</TD><TD>Issuance of patents or other property rights to our competitors or others; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(2)</TD><TD>Inability to obtain or maintain adequate patent or other proprietary rights for our products and services or to successfully
enforce our proprietary rights.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(r)</TD><TD>Development of tests by our competitors or others which we may not be able to license, or usage (or theft) of our technology
or similar technologies or our trade secrets or other intellectual property by competitors, any of which could negatively affect
our competitive position.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(s)</TD><TD>Regulatory delay or inability to commercialize newly developed or licensed tests or technologies or to obtain appropriate reimbursements
for such tests.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(t)</TD><TD>The complexity of billing and revenue recognition for clinical laboratory testing.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(u)</TD><TD>Changes in interest rates and changes in our credit ratings from S&amp;P Global, Moody&rsquo;s Investor Services or Fitch Ratings
causing an unfavorable impact on our cost of and access to capital.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD>Inability to hire or retain qualified or key senior management personnel.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(w)</TD><TD>Terrorist and other criminal activities, hurricanes, earthquakes or other natural disasters, and public health emergencies
and health pandemics, which could affect our customers or suppliers, </TD></TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt">
                                                    <TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">&nbsp;</TD><TD STYLE="width: 0.5in">&nbsp;</TD><TD>transportation or systems, or our facilities, and for which
insurance may not adequately reimburse us.</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(x)</TD><TD>Difficulties and uncertainties in the discovery, development, regulatory environment and/or marketing of new services or solutions
or new uses of existing tests.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(y)</TD><TD>Failure to adapt to changes in the healthcare system (including the medical laboratory testing market) and healthcare delivery,
including those stemming from the Affordable Care Act (or its repeal, amendment or replacement), Protecting Access to Medicare
Act, trends in utilization of the healthcare system and increased patient financial responsibility for services.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(z)</TD><TD>Results and consequences of governmental inquiries.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(aa)</TD><TD>Difficulty in implementing, or lack of success with, our strategic plan.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(bb)</TD><TD>The impact of informatics on our industry and the ability of our Company to adapt to that impact.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(cc)</TD><TD>Failure to adequately operationalize appropriate controls around use of our data, including risk of non-compliance with privacy
law requirements.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 10pt"></A></FONT></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 10pt"><A NAME="UseofProceeds" TITLE="UseofProceeds"></A><B>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We estimate that the net proceeds from
this offering of notes, after deducting underwriting discounts but before deducting other expenses of the offering, will be $545,622,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We expect to use the net proceeds from
this offering for general corporate purposes, which may include the redemption or repayment of indebtedness.&nbsp; The indebtedness
we may redeem or repay includes our $550 million aggregate principal amount of 4.70% Senior Notes and outstanding borrowings under
our senior unsecured revolving credit facility and our secured receivables credit facility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may repay the 4.70% Senior Notes in full
at the April 1, 2021 maturity date or earlier redeem the 4.70% Senior Notes, in whole or in part, pursuant to their terms. As of
April 30, 2020, we had $100&nbsp;million in borrowings outstanding under our senior unsecured revolving credit facility, which
had an interest rate of LIBOR plus 1.125%. The senior unsecured revolving credit facility terminates on March 22, 2023. As of April
30, 2020, we had $100&nbsp;million in borrowings outstanding under our secured receivables credit facility, which had an interest
rate of the commercial paper rate for highly rated issuers or LIBOR, in each case plus 0.70%. The secured receivables credit facility
terminates on October 25, 2021. See &ldquo;Underwriting (Conflicts of Interest)&mdash;Conflicts of Interest.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 10pt"><B></B></FONT></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="Capitalization" TITLE="Capitalization"></A>CAPITALIZATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The following table sets forth our cash
and cash equivalents, debt and total capitalization at March 31, 2020 on an actual basis and as adjusted to reflect the issuance
of the notes offered hereby and assuming the net proceeds of this offering are not immediately applied to redeem or repay indebtedness.
See &ldquo;Use of Proceeds.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The following table should be read together
with our unaudited interim consolidated financial statements and related notes and management&rsquo;s discussion and analysis of
financial condition and results of operations included in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020,
which is incorporated by reference into this prospectus supplement.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2020</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Actual</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As Adjusted</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center">(in millions)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.4pt; width: 56%">Cash and cash equivalents&#9;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; width: 1%">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; width: 12%">342</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; width: 1%">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; width: 12%">886</TD><TD STYLE="vertical-align: top; text-align: left; width: 1%"><SUP>(b)</SUP></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Debt (including current maturities):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 8pt; padding-left: 5.4pt">Secured receivables credit facility<SUP>(a)</SUP>&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 8pt; padding-left: 5.4pt">Senior unsecured revolving credit facility<SUP>(a)</SUP>&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 8pt; padding-left: 5.4pt">4.70% senior notes due 2021&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">553</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">553</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 8pt; padding-left: 5.4pt">4.25% senior notes due 2024&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">319</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">319</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 8pt; padding-left: 5.4pt">3.50% senior notes due 2025&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">627</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">627</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 8pt; padding-left: 5.4pt">3.45% senior notes due 2026&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">513</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">513</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 8pt; padding-left: 5.4pt">4.20% senior notes due 2029&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">499</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">499</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 8pt; padding-left: 5.4pt">2.95% senior notes due 2030&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">798</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">798</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 8pt; padding-left: 5.4pt">6.95% senior notes due 2037&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">175</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">175</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 8pt; padding-left: 5.4pt">5.75% senior notes due 2040&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">245</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">245</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 8pt; padding-left: 5.4pt">4.70% senior notes due 2045&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">300</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">300</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 8pt; padding-left: 5.4pt">Senior notes offered hereby&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">549</TD><TD STYLE="vertical-align: top; text-align: left"><SUP>(c)</SUP></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; text-indent: 8pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Other&#9;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">32</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">32</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 8pt; padding-left: 5.4pt"><FONT STYLE="font-size: 10pt">Debt
    issuance costs&#9;</FONT></TD><TD STYLE="padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(25</FONT></TD><TD STYLE="padding-bottom: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: right"><FONT STYLE="font-size: 10pt">(30</FONT></TD><TD STYLE="padding-bottom: 1pt; font-size: 1pt; text-align: left"><FONT STYLE="font-size: 10pt">)&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 12.5pt; padding-left: 5.4pt">Total debt&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,036</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,580&#9;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 8pt; padding-left: 5.4pt">Stockholders&rsquo; equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 8pt; padding-left: 5.4pt">Quest Diagnostics stockholders&rsquo; equity&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,657</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,657</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 8pt; padding-left: 5.4pt">Noncontrolling interests&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">46</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">46</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1pt; text-indent: 17pt; padding-left: 5.4pt">Total stockholders&rsquo; equity&#9;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,703</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,703</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; text-indent: 26pt; padding-left: 5.4pt">Total capitalization</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">9,739</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">10,283</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>As of April 30, 2020, we had $100 million of outstanding borrowings under each of the secured receivables credit facility and
the senior unsecured revolving credit facility. See &ldquo;Use of Proceeds.&rdquo;</TD></TR></TABLE>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>Cash and cash equivalents, as adjusted, includes the net proceeds from this offering of approximately $544 million, net of
underwriting discounts and other estimated expenses directly related to the offering, which is expected to be used as described
in the &ldquo;Use of Proceeds&rdquo; section in this prospectus supplement.</TD></TR></TABLE>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>Reflects the $550 million aggregate principal amount of 2.800% senior notes due 2031 sold in the offering issued at 99.854%.
The original issue discount of approximately $1 million is reflected as a reduction to the carrying amount of the 2.800% senior
notes due 2031.</TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 10pt"><A NAME="DescriptionofNotes" TITLE="DescriptionofNotes"></A><B>DESCRIPTION
OF NOTES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The 2.800% senior notes due
2031 (the &ldquo;Notes&rdquo;) will be issued under an indenture, dated as
of June&nbsp;27, 2001, as supplemented by the first supplemental indenture, dated as of June&nbsp;27, 2001, each among Quest
Diagnostics, as issuer, the Initial Subsidiary Guarantors (as defined therein), as guarantors, and The Bank of New York, as
trustee, as further supplemented by the second supplemental indenture, dated as of November&nbsp;26, 2001, among Quest
Diagnostics, the Subsidiary Guarantors (as defined therein) and The Bank of New York, as further supplemented by the third
supplemental indenture, dated as of April&nbsp;4, 2002, among Quest Diagnostics, the Additional Subsidiary Guarantors (as
defined therein) and The Bank of New York, as further supplemented by the fourth supplemental indenture, dated as of
March&nbsp;19, 2003, among Quest Diagnostics, the Additional Subsidiary Guarantor (as defined therein) and The Bank of New
York, as further supplemented by the fifth supplemental indenture, dated as of April&nbsp;16, 2004, among Quest Diagnostics,
the Additional Subsidiary Guarantor (as defined therein) and The Bank of New York, as further supplemented by the sixth
supplemental indenture, dated as of October&nbsp;31, 2005, among Quest Diagnostics, the Subsidiary Guarantors (as defined
therein) and The Bank of New York, as further supplemented by the seventh supplemental indenture, dated as of
November&nbsp;21, 2005, among Quest Diagnostics, the Additional Subsidiary Guarantors (as defined therein) and The Bank of
New York, as further supplemented by the eighth supplemental indenture, dated as of July&nbsp;31, 2006, among Quest
Diagnostics, the Additional Subsidiary Guarantors (as defined therein) and The Bank of New York, as further supplemented by
the ninth supplemental indenture, dated as of September&nbsp;30, 2006, among Quest Diagnostics, the Additional Subsidiary
Guarantors (as defined therein) and The Bank of New York, as further supplemented by the tenth supplemental indenture, dated
as of June&nbsp;22, 2007, among Quest Diagnostics, the Subsidiary Guarantors (as defined therein) and The Bank of New York,
as further supplemented by the eleventh supplemental indenture, dated as of June&nbsp;22, 2007, among Quest Diagnostics, the
Additional Subsidiary Guarantors (as defined therein) and The Bank of New York, as further supplemented by the twelfth
supplemental indenture, dated as of June&nbsp;25, 2007, among Quest Diagnostics, the Additional Subsidiary Guarantors (as
defined therein) and The Bank of New York, as further supplemented by the thirteenth supplemental indenture, dated as of
November&nbsp;17, 2009, among Quest Diagnostics, the Subsidiary Guarantors (as defined therein) and The Bank of New York
Mellon, as further supplemented by the fourteenth supplemental indenture, dated as of March&nbsp;24, 2011, among Quest
Diagnostics, the Subsidiary Guarantors (as defined therein) and The Bank of New York Mellon, as further supplemented by the
fifteenth supplemental indenture, dated as of November&nbsp;30, 2011, among Quest Diagnostics, the Additional Subsidiary
Guarantors (as defined therein) and The Bank of New York Mellon, as further supplemented by the sixteenth supplemental
indenture, dated as of March&nbsp;17, 2014, between Quest Diagnostics and The Bank of New York Mellon, as further
supplemented by the seventeenth supplemental indenture, dated as of March&nbsp;10, 2015, between Quest Diagnostics and The
Bank of New York Mellon and as further supplemented by the eighteenth supplemental indenture, dated as of May 26, 2016, among
Quest Diagnostics and The Bank of New York Mellon, as further supplemented by the nineteenth supplemental indenture between
Quest Diagnostics and The Bank of New York Mellon, dated as of March 12, 2019, as further supplemented by the twentieth
supplemental indenture between Quest Diagnostics and The Bank of New York Mellon, dated as of December 16, 2019 and as to be
further supplemented by the twenty-first supplemental indenture between Quest Diagnostics and The Bank of New York Mellon, to
be dated as of the closing date of this offering (collectively, as so supplemented, the &ldquo;Indenture&rdquo;). The terms
of the Notes include those stated in the Indenture and those made part of the Indenture by reference to the Trust Indenture
Act of 1939, as amended (the &ldquo;Trust Indenture Act&rdquo;). A copy of the Indenture is available for inspection at the
office of the trustee during normal business hours following reasonable notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Whenever we refer in this &ldquo;Description
of Notes&rdquo; to terms defined in the Indenture below, such defined terms are incorporated herein by reference. As used in this
&ldquo;Description of Notes,&rdquo; the terms &ldquo;we,&rdquo; &ldquo;our,&rdquo; &ldquo;us&rdquo; and &ldquo;Quest Diagnostics&rdquo;
do not include any current or future subsidiary of Quest Diagnostics Incorporated, unless the context indicates otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The Notes will be initially limited
to $550,000,000 aggregate principal amount and will mature and become due and payable, together with any accrued and unpaid
interest thereon, on June 30, 2031.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Quest Diagnostics may from time to time,
without the consent of the holders of the Notes, issue additional Notes having the same ranking and the same interest rate, maturity
and other terms (except the issue date, public offering price and, if applicable, initial interest payment date) as the Notes.
Any additional Notes and the Notes will generally constitute a single series under the Indenture. This type of offering is often&nbsp;referred
to as a &ldquo;re-opening.&rdquo; Additional Notes may constitute a separate issuance for U.S. federal income tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Interest</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The Notes will bear interest at the
annual rate noted on the cover page&nbsp;of this prospectus supplement. Interest on the Notes will be payable semiannually on
June 30&nbsp;and December 30&nbsp;of each&nbsp;year, beginning December 30, 2020. Interest on the Notes will be paid to
holders of record on June 15&nbsp;or December 15&nbsp;immediately before
the applicable interest payment date. Interest will accrue from May 13,
2020 and will be computed on the basis of a 360-day&nbsp;year of twelve 30-day&nbsp;months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">If any interest payment date, redemption
date or maturity date falls on a&nbsp;day that is not a business&nbsp;day, the payment due on that interest payment date, redemption
date or maturity date will be made on the next succeeding business&nbsp;day, and without any interest or other payment in respect
of such delay.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Seniority; Ranking</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The Notes will be senior unsecured obligations
of Quest Diagnostics and will rank equally with other existing and future senior unsecured obligations of Quest Diagnostics. As
of March 31, 2020, after giving effect to this offering (as if the foregoing had occurred on that date), Quest Diagnostics would
have had total debt outstanding of $4,580&nbsp;million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The Notes will be effectively subordinated
to any secured obligations of Quest Diagnostics to the extent of the value of the assets securing such obligations. The Indenture
does not limit the amount of indebtedness that Quest Diagnostics can incur, but does limit the amount of indebtedness its subsidiaries
that do not guarantee the Notes are permitted to incur (as described below). In addition, the Indenture limits the amount of secured
indebtedness both Quest Diagnostics and its Restricted Subsidiaries may incur pursuant to the covenant described under the heading
&ldquo;&mdash;Limitation on Liens.&rdquo; This covenant is subject to important exceptions described under such heading. As of
March 31, 2020, after giving effect to this offering (as if the foregoing had occurred on that date), Quest Diagnostics would have
had secured debt outstanding of $33 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Quest Diagnostics conducts its operations
through subsidiaries, which generate a substantial portion of its operating income and cash. As a result, distributions or advances
from subsidiaries of Quest Diagnostics are a major source of funds necessary to meet its debt service and other obligations. Contractual
provisions, laws or regulations, as well as any subsidiary&rsquo;s financial condition and operating requirements, may limit the
ability of Quest Diagnostics to obtain cash required to pay Quest Diagnostics&rsquo; debt service obligations, including payments
on the Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The Notes will be structurally subordinated
to all existing and future obligations of Quest Diagnostics&rsquo; subsidiaries, including claims with respect to trade payables.
The subsidiaries of Quest Diagnostics are limited in the amount of Indebtedness they are permitted to incur pursuant to the covenant
described under &ldquo;&mdash;Limitation on Subsidiary Indebtedness and Preferred Stock.&rdquo; This covenant is subject to important
exceptions described under such heading. As of March 31, 2020, after giving effect to this offering (as if the foregoing had occurred
on that date), the subsidiaries of Quest Diagnostics would have had outstanding $32 million of debt, all of which was secured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Our subsidiaries are not guarantors of
the Notes. Certain of our domestic subsidiaries may be required to become subsidiary guarantors of our existing debt securities
if they incur or assume any Indebtedness, subject to exceptions set forth in the Indenture, or guarantee any Indebtedness of our
Company when the amount of such Indebtedness, together with any other outstanding Indebtedness of our Company guaranteed by our
subsidiaries that do not guarantee our existing debt securities, exceeds $50&nbsp;million in the aggregate at any time. To the
extent the Indenture requires any domestic Subsidiary of our Company to guarantee our Company&rsquo;s existing debt securities</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">
issued under the Indenture prior to December 2019, any such Subsidiary will be required to guarantee the Notes in a substantially
consistent manner for so long as such Subsidiary guarantees such existing debt securities. See &ldquo;&mdash;Future Subsidiary
Guarantors.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Optional Redemption</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Prior to March 30,
2031 (three months prior to their maturity date, the &ldquo;Par Call
Date&rdquo;), the Notes may be redeemed, as a whole at any time or in part from time to time, at the option of Quest
Diagnostics, on at least 10&nbsp;days, but not more than 60&nbsp;days, prior notice mailed to the registered address of each
holder of the Notes, at a redemption price equal to the greater of:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>100% of principal amount of the Notes to be redeemed, and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>the sum of the present values of the Remaining Scheduled Payments (as defined below) discounted, on a semiannual basis,
                                                                                                           assuming a 360-day&nbsp;year consisting of twelve 30-day&nbsp;months, at the Treasury Rate (as defined below) plus 35 basis
                                                                                                           points,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">plus
accrued interest to, but excluding, the date of redemption, which has not been paid. The make-whole calculation will not include
any discounted amount with respect to the interest and principal payments due on the maturity date of the Notes and will instead
include the discounted amount with respect to the interest and principal payments that would be payable upon redemption of the
Notes on the Par Call Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">On or after the Par Call Date, the Notes
may be redeemed, as a whole at any time or in part from time to time, at the option of Quest Diagnostics, on at least 10&nbsp;days,
but not more than 60&nbsp;days, prior notice mailed to the registered address of each holder of the Notes, at a redemption price
equal to 100% of the principal amount of the Notes being redeemed plus accrued interest to, but excluding, the date of redemption,
which has not been paid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Remaining Scheduled Payments&rdquo;
means, with respect to the Notes to be redeemed, the remaining scheduled payments of the principal thereof and interest thereon
from the redemption date through the Par Call Date; <I>provided</I>, <I>however</I>, that, if such redemption date is not an interest
payment date with respect to the Notes, the amount of the next succeeding scheduled interest payment thereon will be deemed to
be reduced by the amount of interest accrued thereon to such redemption date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Treasury Rate&rdquo; means, with
respect to any redemption date for the Notes, the rate per annum equal to the semiannual equivalent yield to maturity or interpolation
(on a day count basis) of the interpolated Comparable Treasury Issue, assuming a price for the Comparable Treasury Issue (expressed
as a percentage of its principal amount) equal to the Comparable Treasury Price for such redemption date, as determined by Quest
Diagnostics or an Independent Investment Banker appointed by Quest Diagnostics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The Treasury Rate will be calculated
on the third business&nbsp;day preceding the redemption date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Comparable Treasury Issue&rdquo;
means the United States Treasury security selected by an Independent Investment Banker as having a maturity comparable to the remaining
term of the Notes to be redeemed (assuming the Notes matured on the Par Call Date) that would be utilized, at the time of selection
and in accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity
to the remaining term of the Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Independent Investment Banker&rdquo;
means one&nbsp;of the Reference Treasury Dealers, to be appointed by Quest Diagnostics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Comparable Treasury Price&rdquo;
means, with respect to any redemption date for the Notes:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>the average of four&nbsp;Reference Treasury Dealer Quotations for that redemption date, after excluding the highest and lowest
of such Reference Treasury Dealer Quotations; or</TD></TR></TABLE>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>if Quest Diagnostics obtains fewer than four&nbsp;Reference Treasury Dealer Quotations, the average of all quotations obtained
by Quest Diagnostics.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Reference Treasury Dealer Quotations&rdquo;
means, with respect to each Reference Treasury Dealer and any redemption date, the average, as determined by Quest Diagnostics,
of the bid and asked prices for the Comparable Treasury Issue, expressed in each case as a percentage of its principal amount,
quoted in writing to the trustee by such Reference Treasury Dealer at 3:30 p.m., New York City time, on the third business&nbsp;day
preceding such redemption date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Reference Treasury Dealer&rdquo;
means a primary U.S. Government securities dealer, which we refer to as &ldquo;Primary Treasury Dealer,&rdquo; selected by Quest
Diagnostics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">On and after the redemption date for
the Notes, interest will cease to accrue on the Notes or any portion thereof called for redemption, unless Quest Diagnostics defaults
in the payment of the redemption price and accrued interest. On or before the redemption date for the Notes, Quest Diagnostics
shall deposit with a paying agent, or the trustee, funds sufficient to pay the redemption price of and accrued interest on such
Notes to be redeemed on such date. If less than all of the Notes are to be redeemed, and such Notes are at the time represented
by one&nbsp;or more global security certificates, then the Notes to be redeemed will be selected in accordance with the procedures
of the depositary. If less than all of the Notes are to be redeemed, and such Notes are not represented by one&nbsp;or more global
security certificates, the Notes to be redeemed shall be selected by such method as the trustee shall deem fair and appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Change of Control</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">If a Change of Control Triggering Event
occurs, unless Quest Diagnostics has exercised its option to redeem the Notes as described above, Quest Diagnostics will be required
to make an offer (the &ldquo;Change of Control Offer&rdquo;) to each holder of the Notes to repurchase all or any part (equal to
$2,000 or an integral multiple of $1,000 in excess thereof) of that holder&rsquo;s Notes on the terms set forth in the Notes. In
the Change of Control Offer, Quest Diagnostics will be required to offer payment in cash equal to 101% of the aggregate principal
amount of Notes repurchased, plus accrued and unpaid interest, if any, on the Notes repurchased to, but excluding, the date of
repurchase (the &ldquo;Change of Control Payment&rdquo;). Within 30&nbsp;days following any Change of Control Triggering Event
or, at Quest Diagnostics&rsquo; option, prior to any Change of Control, but after public announcement of the transaction that constitutes
or may constitute the Change of Control, a notice will be mailed to holders of the Notes describing the transaction that constitutes
or may constitute the Change of Control Triggering Event and offering to repurchase the Notes on the date specified in the notice,
which date will be no earlier than 30&nbsp;days and no later than 60&nbsp;days from the date such notice is mailed (the &ldquo;Change
of Control Payment Date&rdquo;). The notice will, if mailed prior to the date of consummation of the Change of Control, state that
the offer to purchase is conditioned on the Change of Control Triggering Event occurring on or prior to the Change of Control Payment
Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">On the Change of Control Payment Date,
Quest Diagnostics will, to the extent lawful:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>accept for payment all Notes or portions of Notes properly tendered pursuant to the Change of Control Offer;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>deposit with the paying agent an amount equal to the Change of Control Payment in respect of all Notes or portions of Notes
properly tendered; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>deliver or cause to be delivered to the trustee the Notes properly accepted together with an Officers&#8217; Certificate stating
the aggregate principal amount of Notes or portions of Notes being repurchased.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Quest Diagnostics will not be required
to make a Change of Control Offer upon the occurrence of a Change of Control Triggering Event if a third party makes such an offer
in the manner, at the times and otherwise in compliance with the requirements for an offer made by Quest Diagnostics and the third
party repurchases all Notes properly tendered and not withdrawn under its offer. In addition, Quest Diagnostics will not repurchase
any Notes if </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">there
has occurred and is continuing on the Change of Control Payment Date an event of default under the Indenture, other than a default
in the payment of the Change of Control Payment upon a Change of Control Triggering Event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Quest Diagnostics will comply with the
requirements of Rule&nbsp;14e-1 under the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), and any
other securities laws and regulations thereunder to the extent those laws and regulations are applicable in connection with the
repurchase of the Notes as a result of a Change of Control Triggering Event. To the extent that the provisions of any such securities
laws or regulations conflict with the Change of Control Offer provisions of the Notes, Quest Diagnostics will comply with those
securities laws and regulations and will not be deemed to have breached its obligations under the Change of Control Offer provisions
of the Notes by virtue of any such conflict. For purposes of the Change of Control Offer provisions of the Notes, the following
terms will be applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Change of Control&rdquo; means
the occurrence of any of the following: (1)&nbsp;the consummation of any transaction (including, without limitation, any merger
or consolidation) the result of which is that any &ldquo;person&rdquo; (as that term is used in Section&nbsp;13(d) (3)&nbsp;of
the Exchange Act) (other than Quest Diagnostics or one&nbsp;of its subsidiaries) becomes the beneficial owner (as defined in Rules&nbsp;13d-3
and 13d-5 under the Exchange Act), directly or indirectly, of more than 50% of the voting stock of Quest Diagnostics or other voting
stock into which the voting stock of Quest Diagnostics is reclassified, consolidated, exchanged or changed, measured by voting
power rather than number of shares; (2)&nbsp;the direct or indirect sale, transfer, conveyance or other disposition (other than
by way of merger or consolidation), in one&nbsp;or more series of related transactions, of all or substantially all of Quest Diagnostics&rsquo;
assets and the assets of its subsidiaries, taken as a whole, to one&nbsp;or more &ldquo;persons&rdquo; (as that term is defined
in the Indenture) (other than Quest Diagnostics or one&nbsp;of its subsidiaries); or (3)&nbsp;the first&nbsp;day on which a majority
of the members of the Board of Directors of Quest Diagnostics are not Continuing Directors. Notwithstanding the foregoing, a transaction
will not be deemed to involve a Change of Control if (1)&nbsp;Quest Diagnostics becomes a direct or indirect wholly-owned subsidiary
of a holding company and (2)(A) the direct or indirect holders of the voting stock of such holding company immediately following
that transaction are substantially the same as the holders of the voting stock of Quest Diagnostics immediately prior to that transaction
or (B) immediately following that transaction no person (other than a holding company satisfying the requirements of this sentence)
is the beneficial owner, directly or indirectly, of more than 50% of the voting stock of such holding company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Change of Control Triggering Event&rdquo;
means the occurrence of both a Change of Control and a Rating event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Continuing Directors&rdquo; means,
as of any date of determination, any member of Quest Diagnostics&rsquo; Board of Directors who (1)&nbsp;was a member of such Board
of Directors on the date the Notes were issued or (2)&nbsp;was nominated for election, elected or appointed to such Board of Directors
with the approval of a majority of the Continuing Directors who were members of such Board of Directors at the time of such nomination,
election or appointment (either by a specific vote or by approval of the proxy statement of Quest Diagnostics in which such member
was named as a nominee for election as a director, without objection to such nomination).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Fitch&rdquo; means Fitch Ratings,
Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Investment Grade Rating&rdquo;
means a rating equal to or higher than Baa3 (or the equivalent) by Moody&rsquo;s, BBB&minus; (or the equivalent) by S&amp;P and
BBB&minus; (or the equivalent) by Fitch, and the equivalent investment grade credit rating from any additional rating agency or
Rating Agencies selected by Quest Diagnostics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Moody&rsquo;s&rdquo; means Moody&rsquo;s
Investors Service, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Rating Agencies&rdquo; means (1)&nbsp;each
of Moody&rsquo;s, S&amp;P and Fitch; and (2)&nbsp;if any of Moody&rsquo;s, S&amp;P or Fitch ceases to rate the Notes or fails to
make a rating of the Notes publicly available for reasons outside of the control of Quest Diagnostics, a &ldquo;nationally recognized
statistical rating organization&rdquo; within the meaning of Section&nbsp;3(a)(62) of the Exchange Act selected by Quest Diagnostics
(as certified by a resolution of the Board of Directors) as a replacement agency for Moody&rsquo;s, S&amp;P or Fitch, or all of
them, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Rating event&rdquo; means the
rating on the Notes is lowered by at least two&nbsp;of the Rating Agencies and the Notes are rated below an Investment Grade Rating
by at least two&nbsp;of the Rating Agencies on any&nbsp;day within the 60-day period (which 60-day period will be extended so long
as the rating of the Notes is under publicly announced consideration for a possible downgrade by any of the Rating Agencies) after
the earlier of (1)&nbsp;the occurrence of a Change of Control and (2)&nbsp;public notice of the occurrence of a Change of Control
or the intention of Quest Diagnostics to effect a Change of Control; <I>provided</I>, <I>however</I>, that a Rating event otherwise
arising by virtue of a particular reduction in rating will not be deemed to have occurred in respect of a particular Change of
Control (and thus will not be deemed a Rating event for purposes of the definition of Change of Control Triggering Event) if the
Rating Agencies making the reduction in rating to which this definition would otherwise apply do not announce or publicly confirm
or inform the trustee in writing at its request or the request of Quest Diagnostics that the reduction was the result, in whole
or in part, of any event or circumstance comprised of or arising as a result of, or in respect of, the applicable Change of Control
(whether or not the applicable Change of Control has occurred at the time of the Rating event).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;S&amp;P&rdquo; means S&amp;P Global
Ratings, a division of S&amp;P Global Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Voting stock&rdquo; means, with
respect to any specified &ldquo;person&rdquo; (as that term is used in Section&nbsp;13(d)(3) of the Exchange Act) as of any date,
the capital stock of such person that is at the time entitled to vote generally in the election of the board of directors of such
person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Sinking Fund</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The Notes will not be entitled to the
benefit of any sinking fund.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Limitation on Liens</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Other than as provided under &ldquo;&mdash;Exempted
Liens and Sale and Leaseback Transactions,&rdquo; Quest Diagnostics will not, and will not permit any Restricted Subsidiary to,
create or assume any Indebtedness secured by any Lien on any Principal Property or shares of stock or Indebtedness of any Restricted
Subsidiary, unless: (1)&nbsp;in the case of Quest Diagnostics, the Notes are secured by such Lien equally and ratably with, or
prior to, the Indebtedness secured by such Lien, or (2)&nbsp;in the case of any domestic Subsidiary that has guaranteed the Notes,
such Subsidiary&rsquo;s guarantee of the Notes is secured by such Lien equally and ratably with, or prior to, the Indebtedness
secured by such Lien. The restrictions do not apply to Indebtedness that is secured by:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Liens existing on the date of the issuance of the Notes;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Liens securing only the Notes;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Liens in favor of only Quest Diagnostics or any Restricted Subsidiary;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Liens on property or shares of stock or indebtedness of a Person existing at the time such Person becomes a Restricted Subsidiary
or is merged into or consolidated with, or its assets are acquired by, Quest Diagnostics or any Restricted Subsidiary (<I>provided</I>
that such Lien was not incurred in anticipation of such transaction and was in existence prior to such transaction) so long as
such Lien does not extend to any other property and the Indebtedness so secured is not increased;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Liens on property existing immediately prior to the acquisition thereof (<I>provided</I> that such Lien was not incurred in
anticipation of such transaction and was in existence prior to such transaction) so long as such Lien does not extend to any other
property and the Indebtedness so secured is not increased;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Liens to secure Indebtedness incurred for the purpose of financing all or any part of a property&#8217;s purchase price or
cost of construction or additions, repairs, alterations, or other improvements; <I>provided</I> that (1)&nbsp;the principal amount
of any Indebtedness secured by such Lien does not exceed 100% of such property&#8217;s purchase price or cost, (2)&nbsp;such Lien
does not extend to or cover any </TD></TR></TABLE>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt">                                                                                                                                         <TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">&nbsp;</TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol"></TD><TD>other property other than the property so purchased, constructed or on which such additions, repairs,
alterations or other improvements were so made, and (3)&nbsp;such Lien is incurred prior to or within 270&nbsp;days after the acquisition
of such property or the completion of construction or such additions, repairs, alterations or other improvements and the full operation
of such property thereafter;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Liens in favor of the United States or any state thereof, or any instrumentality of either, to secure certain payments pursuant
to any contract or statute;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Liens for taxes or assessments or other governmental charges or levies which are being contested in good faith and for which
adequate reserves are being maintained, to the extent required by generally accepted accounting principles;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>title exceptions, easements and other similar Liens that are not consensual and that do not materially impair the use of the
property subject thereto;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Liens to secure obligations under workmen&#8217;s compensation laws, unemployment compensation, old-age pensions and other
social security benefits or similar legislation, including Liens with respect to judgments which are not currently dischargeable;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Liens arising out of legal proceedings, including Liens arising out of judgments or awards;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>warehousemen&#8217;s, materialmen&#8217;s and other similar Liens for sums being contested in good faith and for which adequate
reserves are being maintained, to the extent required by generally accepted accounting principles;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Liens incurred to secure the performance of statutory obligations, surety or appeal bonds, performance or return-of-money bonds
or other obligations of a like nature incurred in the ordinary course of business; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Liens to secure any extension, renewal, refinancing or refunding (or successive extensions, renewals, refinancings or refundings),
in whole or in part, of any Indebtedness secured by Liens referred to in the foregoing bullets or liens created in connection with
any amendment, consent or waiver relating to such Indebtedness, so long as such Lien does not extend to any other property and
the Indebtedness so secured does not exceed the fair market value (as determined by our board of directors) of the assets subject
to such Liens at the time of such extension, renewal, refinancing or refunding, or such amendment, consent or waiver, as the case
may be.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Limitation on Sale and Leaseback Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Other than as provided under &ldquo;&mdash;Exempted
Liens and Sale and Leaseback Transactions,&rdquo; Quest Diagnostics will not, and will not permit any Restricted Subsidiary to,
enter into any Sale and Leaseback Transaction with respect to any Principal Property unless:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>the Sale and Leaseback Transaction is solely with Quest Diagnostics or a domestic Subsidiary that has guaranteed the Notes;
or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>the lease is for a period not in excess of five&nbsp;years, including renewal rights; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Quest Diagnostics or the Restricted Subsidiary, prior to or within 270&nbsp;days after the sale of such Principal Property
in connection with the Sale and Leaseback Transaction is completed, applies the net cash proceeds of the sale of the Principal
Property leased to:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(1)</TD><TD>the retirement of the Notes or debt ranking equally with the Notes of Quest Diagnostics or any Restricted Subsidiary, or</TD></TR></TABLE>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(2)</TD><TD>the acquisition of different property, facilities or equipment or the expansion of Quest Diagnostics&rsquo; existing business,
including the acquisition of other businesses.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Exempted Liens and Sale and Leaseback Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Notwithstanding the restrictions described
under the headings &ldquo;&mdash;Limitation on Liens&rdquo; or &ldquo;&mdash;Limitation on Sale and Leaseback Transactions,&rdquo;
Quest Diagnostics or any Restricted Subsidiary may create or assume any Liens or enter into any Sale and Leaseback Transactions
not otherwise permitted as described above, if the sum of the following does not exceed 10% of Consolidated Total Assets:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>the outstanding Indebtedness secured by such Liens (not including any Liens permitted under &#8220;&#8212; Limitation on Liens&#8221;
which amount does not include any Liens permitted under the provisions of this &#8220;&#8212;Exempted Liens and Sale and Leaseback
Transactions&#8221;); plus</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>all Attributable Debt in respect of such Sale and Leaseback Transaction entered into (not including any Sale and Leaseback
Transactions permitted under &#8220;&#8212;Limitation on Sale and Leaseback Transactions&#8221; which amount does not include any
Sale and Leaseback Transactions permitted under the provisions of this &#8220;&#8212;Exempted Liens and Sale and Leaseback Transactions&#8221;),</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">measured, in each case, at the time such Lien is incurred
or any such Sale and Leaseback Transaction is entered into by Quest Diagnostics or the Restricted Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Limitation on Subsidiary Indebtedness and Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">None&nbsp;of the Subsidiaries of Quest
Diagnostics other than a domestic Subsidiary that has guaranteed the Notes may, directly or indirectly, create, incur, issue, assume
or extend the maturity of any Indebtedness (including Acquired Indebtedness) or Preferred Stock except for the following, <I>provided</I>
that, for purposes of this covenant, any Acquired Indebtedness shall not be deemed to have been incurred until 270&nbsp;days from
the date (1)&nbsp;the Person obligated on such Acquired Indebtedness becomes a Subsidiary of Quest Diagnostics or (2)&nbsp;the
acquisition of assets, in connection with which such Acquired Indebtedness was assumed, is consummated:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Indebtedness outstanding on the date of the Indenture;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Indebtedness representing the assumption by one&nbsp;Subsidiary of Indebtedness of another Subsidiary;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Indebtedness outstanding under any Receivables Credit Facility;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Indebtedness secured by a Lien incurred for the purpose of financing all or any part of a property&#8217;s purchase price or
cost of construction or additions, repairs, alterations or other improvements, <I>provided</I> that such Indebtedness and Lien
is incurred prior to or within 270&nbsp;days after the acquisition of such property or the completion of construction or such additions,
repairs, alterations or other improvements and the full operation of such property thereafter;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Indebtedness of any Subsidiary of Quest Diagnostics, the proceeds of which are used to renew, extend, refinance or refund outstanding
Indebtedness of such Subsidiary; <I>provided</I> that such Indebtedness is scheduled to mature no earlier than the Indebtedness
being renewed, extended, refinanced or refunded; <I>provided further</I> that such Indebtedness shall be permitted hereunder only
to the extent that the aggregate principal amount of such Indebtedness (or, if such Indebtedness is issued at a price less than
the principal amount thereof, the aggregate amount of gross proceeds therefrom) does not exceed the aggregate principal amount
then outstanding under the Indebtedness being renewed, extended, refinanced or refunded (or if the Indebtedness being renewed,
extended, refinanced or refunded, was issued at a price less than the principal amount thereof, then not in excess of the amount
of liability in respect thereof determined in accordance with generally accepted accounting principles) plus the lesser of (A)&nbsp;the
stated amount of any </TD></TR></TABLE>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt">                                                                                                                                                                                                                                                                                                                                                                                                                           <TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">&nbsp;</TD><TD STYLE="width: 0.5in">&nbsp;</TD><TD>premium or other payment required to be paid in connection with such a refinancing pursuant to the terms of
the Indebtedness being refinanced or (B)&nbsp;the amount of premium or other payment actually paid at such time to refinance the
Indebtedness, plus, in either case, the amount of expenses of such Subsidiary incurred in connection with such refinancing;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Indebtedness of a Subsidiary of Quest Diagnostics to Quest Diagnostics or to another Subsidiary of Quest Diagnostics;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>any Indebtedness resulting from a Sale and Leaseback Transaction which is permitted by the &#8220;&#8212;Limitation on Sale
and Leaseback Transactions&#8221; covenant (but not including any Sale and Leaseback Transaction which is permitted by the &#8220;&#8212;Exempted
Liens and Sale and Leaseback Transactions&#8221; provisions relating thereto);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>any Permitted Acquired Indebtedness;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>any guarantee of Indebtedness of Quest Diagnostics by any Subsidiary of Quest Diagnostics in anticipation of such Subsidiary
guaranteeing the obligations of Quest Diagnostics pursuant to the terms of the Indenture;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Preferred Stock to the extent that the aggregate liquidation preference of Preferred Stock, outstanding at any one&nbsp;time,
does not exceed 5% of Consolidated Total Assets;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>shares of Preferred Stock held by Quest Diagnostics or a subsidiary of Quest Diagnostics; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>any Indebtedness, including any Acquired Indebtedness that is not Permitted Acquired Indebtedness, the outstanding aggregate
principal amount of which does not at any one&nbsp;time exceed the greater of (1)&nbsp;10% of Consolidated Total Assets or (2)&nbsp;$200&nbsp;million,
measured in each case at the time such Indebtedness is incurred.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Merger, Consolidation or Sale of Assets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Quest Diagnostics may merge or consolidate
with another Person and may sell, transfer or lease all or substantially all of its assets to another Person if all the following
conditions are met:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>The merger, consolidation or sale of assets must not cause an event of default. See &#8220;&#8212;Events of Default.&#8221;
An event of default for this purpose would also include any event that would be an event of default if the notice or time requirements
were disregarded;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>If Quest Diagnostics is not the surviving entity, the Person we would merge or consolidate with, or sell all or substantially
all of our assets to, must be organized under the laws of the United States or any state thereof;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>If Quest Diagnostics is not the surviving entity, the Person we would merge or consolidate with, or sell all or substantially
all of our assets to, must expressly assume by supplemental indenture all of our obligations under the Notes and the Indenture;
and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Quest Diagnostics must deliver specific certification and documents to the trustee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Events of Default</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The term &ldquo;Event of Default&rdquo;
in respect of the Notes means any of the following:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B></B></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Quest Diagnostics or any domestic Subsidiary that guarantees the obligations of Quest Diagnostics pursuant to the terms of
the Indenture does not pay the principal of or any premium on the Notes on its due date;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Quest Diagnostics or any domestic Subsidiary that guarantees the obligations of Quest Diagnostics pursuant to the terms of
the Indenture does not pay interest on the Notes within 30&nbsp;days of its due date whether at maturity, upon redemption or upon
acceleration;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Quest Diagnostics or any domestic Subsidiary that guarantees the obligations of Quest Diagnostics pursuant to the terms of
the Indenture remains in breach of a covenant in respect of the Notes for 60&nbsp;days after it receives a written&nbsp;notice
of default stating it is in breach and requiring that it remedy the breach. The notice must be sent by either the trustee or holders
of 25% of the aggregate principal amount of the Notes;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>An event of default under any indenture or instrument evidencing or under which Quest Diagnostics or any domestic Subsidiary
that guarantees the obligations of Quest Diagnostics pursuant to the terms of the Indenture then has outstanding any Indebtedness
shall occur and be continuing and either:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(1)</TD><TD>such event of default results from the failure to pay the principal of such Indebtedness in excess of $200&nbsp;million at
final maturity of such Indebtedness, individually or in the aggregate; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(2)</TD><TD>as a result of such event of default the maturity of such Indebtedness shall have been accelerated so that the same shall be
or become due and payable prior to the date on which the same would otherwise have become due and payable and the principal amount
of such Indebtedness, together with the principal of any other Indebtedness of Quest Diagnostics or such Subsidiary in default,
or the maturity of which has been accelerated, aggregates at least $200&nbsp;million, individually or in the aggregate;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Any domestic Subsidiary that guarantees the obligations of Quest Diagnostics pursuant to the terms of the Indenture repudiates
its obligations under its guarantee of the Notes or, other than by reason of the termination of the Indenture or the release of
any such guarantee in accordance with the Indenture, any such guarantee ceases to be in full force and effect or is declared null
and void and such condition shall have continued for a period of 30&nbsp;days after written&nbsp;notice of such failure requiring
Quest Diagnostics or such Subsidiary to remedy the same shall have been given to Quest Diagnostics by the trustee or to Quest Diagnostics
and the trustee by the holders of 25% in aggregate principal amount of the Notes then outstanding; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Quest Diagnostics or any domestic Subsidiary that guarantees the obligations of Quest Diagnostics pursuant to the terms of
the Indenture files for bankruptcy or certain other events of bankruptcy, insolvency or reorganization occur.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The trustee may withhold notice to the
holders of Notes of any default (except in the payment of principal or interest) if it considers such withholding of notice to
be in the best interests of the holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">If an event of default with respect to
the Notes has occurred and has not been cured, the trustee or the holders of 25% in aggregate principal amount of the Notes may
declare the entire principal amount (and premium, if any) of, and all the accrued interest on the Notes to be due and immediately
payable. This is called a declaration of acceleration of maturity. If an event of default with respect to the Notes occurs because
of certain events in bankruptcy, insolvency or reorganization, the principal amount of the Notes will be automatically accelerated,
without any action by the trustee or any holder. Holders of a majority in principal amount of the Notes may also waive certain
past defaults under the Indenture on behalf of all of the holders of the Notes. A declaration of acceleration of maturity with
respect to the Notes may be canceled, under specific circumstances, by the holders of at least a majority in principal amount of
the Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Except in cases of default, where the
trustee has some special duties, the trustee is not required to take any action under the Indenture at the request of any of the
holders unless the holders offer the trustee protection reasonably satisfactory to it from expenses and liability called an &ldquo;indemnity.&rdquo;
If indemnity satisfactory to the trustee is provided, the holders of a majority in principal amount of the Notes may, with respect
to the Notes, direct in writing the time, method and place of conducting any lawsuit or other formal legal action seeking any remedy
available to the trustee. The trustee may refuse to follow those directions in certain circumstances. No delay or omission in exercising
any right or remedy will be treated as a waiver of the right, remedy or event of default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Before you are allowed to bypass the
trustee and bring a lawsuit or other formal legal action or take other steps to enforce your rights or protect your interests relating
to the Notes, the following must occur:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>You must give the trustee written&nbsp;notice that an event of default has occurred and remains uncured;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>The holders of at least 25% in principal amount of the outstanding Notes must make a written&nbsp;request that the trustee
take action because of the default and must offer the trustee indemnity reasonably satisfactory to it against the cost and other
liabilities of taking that action;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>The trustee must not have taken action for 60&nbsp;days after receipt of the above notice and offer of indemnity; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Holders of a majority in principal amount of the Notes must not have given the trustee a direction inconsistent with the above
notice.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">However, you are entitled at any time
to bring a lawsuit for the payment of money due on your Notes on or after the due date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Defeasance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><I>Full Defeasance</I>. If there is a
change in federal tax law, as described below, we can legally release ourselves and any domestic Subsidiary that guarantees our
obligations pursuant to the terms of the Indenture from any payment or other obligations on the Notes, called &ldquo;full defeasance,&rdquo;
if we put in place the following other arrangements for you to be repaid:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>We must deposit in trust for your benefit and the benefit of all other registered holders of the Notes a combination of money
and U.S. government or U.S. government agency notes or bonds that will generate enough cash to make interest, principal and any
other payments on the Notes on their various due dates including, possibly, their earliest redemption date.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>In order for us to effect a full defeasance, we must deliver to the trustee a legal opinion confirming that you will not recognize
income, gain or loss for U.S. federal income tax purposes as a result of the defeasance and that you will not be taxed on the Notes
any differently than if the defeasance had not occurred.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">If we accomplish full defeasance, as
described above, you would have to rely solely on the trust deposit for repayment on the Notes. You could not look to us for repayment
in the unlikely event of any shortfall. Conversely, the trust deposit would most likely be protected from claims of our lenders
and other creditors if we ever become bankrupt or insolvent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><I>Covenant Defeasance</I>. We can make
the same type of deposit described above and be released and cause any domestic Subsidiary that guarantees our obligations pursuant
to the terms of the Indenture to be released from the restrictive covenants in the Notes, if any. This is called &ldquo;covenant
defeasance.&rdquo; In that event, you would lose the protection of those restrictive covenants but would gain the protection of
having money and securities set aside in trust to repay the Notes. In order to achieve covenant defeasance, we must do the following:</P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>We must deposit in trust for your benefit and the benefit of all other registered holders of the Notes a combination of money
and U.S. government or U.S. government agency notes or bonds that will generate enough cash to make interest, principal and any
other payments on the Notes on their various due dates.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>We must deliver to the trustee a legal opinion confirming that under current U.S. federal income tax law you will not recognize
income, gain or loss for U.S. federal income tax purposes as a result of the covenant defeasance and that you will not be taxed
on the Notes any differently than if the covenant defeasance had not occurred.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">If we accomplish covenant defeasance,
the following provisions of the Indenture and the Notes would no longer apply unless otherwise specified:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>any promises of any domestic Subsidiary that guarantees our obligations pursuant to the terms of the Indenture relating to
its guarantees, the conduct of its business and any other covenants applicable to the Notes;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>our promises regarding conduct of our business and other matters and any other covenants applicable to the Notes; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>the definition of an event of default as a breach of such covenants.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">If we accomplish covenant defeasance,
you can still look to us and any domestic Subsidiary that guarantees our obligations pursuant to the terms of the Indenture for
repayment of the Notes if there were a shortfall in the trust deposit. In fact, if one&nbsp;of the remaining events of default
occurred (such as our bankruptcy) and the Notes become immediately due and payable, there may be such a shortfall. Depending on
the event causing the default, of course, you may not be able to obtain payment of the shortfall.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">In order to exercise either full defeasance
or covenant defeasance, we must comply with certain conditions, and no event or condition can exist that would prevent us and any
domestic Subsidiary that guarantees our obligations pursuant to the terms of the Indenture from making payments of principal, premium,
and interest, if any, on the Notes on the date the irrevocable deposit is made or at any time during the period ending on the 91st&nbsp;day
after the deposit date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Notices</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">With respect to the Notes, we and the
trustee will send notices regarding the Notes only to registered holders, using their addresses as listed in the list of registered
holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Future Subsidiary Guarantors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The Notes do not currently benefit from
any guarantees from any of Quest Diagnostics&rsquo; subsidiaries. To the extent the Indenture governing the existing debt securities
requires any domestic Subsidiary of Quest Diagnostics to guarantee Quest Diagnostics&rsquo; existing debt securities issued under
the Indenture, any such Subsidiary will be required to guarantee the Notes in a substantially consistent manner for so long as
such Subsidiary guarantees such existing debt securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Global Notes: Book-Entry System</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B><I>Global Notes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The Notes will be represented by one&nbsp;or
more fully registered global notes, without interest coupons and will be deposited upon issuance with the trustee as custodian
for The Depository Trust Company, New York, New York (&ldquo;DTC&rdquo;), and registered in the name of DTC or its nominee, in
each case, for credit to an account of a direct or indirect participant as described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Except as set forth below, the global
notes may be transferred, in whole and not in part, only to another nominee of DTC or to a successor of DTC or its nominee. Beneficial
interests in the global notes may not be exchanged for definitive notes in registered certificated form (&ldquo;certificated notes&rdquo;)
except in the limited circumstances described below. See &ldquo;&mdash;Certain Book-Entry Procedures for the Global Notes.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Except in the limited circumstances described
below, owners of beneficial interests in the global notes will not be entitled to receive physical delivery of notes in certificated
form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Transfers of beneficial interests in
the global notes are subject to the applicable rules and procedures of DTC and its direct or indirect participants, which may change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The Notes may be presented for registration
of transfer and exchange at the offices of the trustee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B><I>Certain Book-Entry Procedures for the Global Notes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">All interests in the global notes will
be subject to the operations and procedures of DTC, Euroclear and Clearstream Luxembourg. The descriptions of the operations and
procedures of DTC, Euroclear and Clearstream Luxembourg set forth below are provided solely as a matter of convenience. These operations
and procedures are solely within the control of the respective settlement systems and are subject to change by them from time to
time. We obtained the information in this section and elsewhere in this prospectus supplement concerning DTC, Euroclear and Clearstream
Luxembourg and their respective book-entry systems from sources that we believe are reliable, but we take no responsibility for
the accuracy of any of this information, and investors are urged to contact the relevant system or its participants directly to
discuss these matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><I>DTC</I>. DTC has advised us that it
is:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>a limited-purpose trust company organized under the laws of the State of New York;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>a &#8220;banking organization&#8221; within the meaning of the New York State Banking Law;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>a member of the Federal Reserve System;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>a &#8220;clearing corporation&#8221; within the meaning of the New York Uniform Commercial Code, as amended; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>a &#8220;clearing agency&#8221; registered pursuant to Section&nbsp;17A of the Exchange Act.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">DTC was created to hold securities for
its participants (collectively, the &ldquo;participants&rdquo;) and to facilitate the clearance and settlement of securities transactions
between its participants through electronic book-entry changes to the accounts of its participants, thereby eliminating the need
for physical transfer and delivery of certificates. DTC&rsquo;s participants include securities brokers and dealers (including
some or all of the underwriters), banks and trust companies, clearing corporations and certain other organizations. Indirect access
to DTC&rsquo;s system is also available to other entities such as Clearstream Luxembourg, Euroclear, banks, brokers, dealers and
trust companies (collectively, the &ldquo;indirect participants&rdquo;) that clear through or maintain a custodial relationship
with a participant, either directly or indirectly. Investors who are not participants may beneficially own securities held by or
on behalf of DTC only through participants or indirect participants in DTC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><I>Clearstream Luxembourg</I>. Clearstream
Luxembourg is incorporated under the laws of Luxembourg as a professional depositary. Clearstream Luxembourg holds securities for
its participating organizations (&ldquo;Clearstream Luxembourg Participants&rdquo;) and facilitates the clearance and settlement
of securities transactions between Clearstream Luxembourg Participants through electronic book-entry changes in accounts of Clearstream
Luxembourg Participants, thereby eliminating the need for physical movement of certificates. Clearstream Luxembourg provides Clearstream
Luxembourg Participants with, among other things, services for safekeeping, administration, clearance and establishment of internationally
traded securities and securities lending and borrowing. Clearstream Luxembourg interfaces with domestic markets in several countries.
As a professional depositary, </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">Clearstream
Luxembourg is subject to regulation by the Luxembourg Monetary Institute. Clearstream Luxembourg Participants are recognized financial
institutions around the world, including underwriters, securities brokers and dealers, banks, trust companies, clearing corporations
and certain other organizations, and may include the underwriters. Indirect access to Clearstream Luxembourg is also available
to others, such as banks, brokers, dealers and trust companies that clear through or maintain a custodial relationship with a
Clearstream Luxembourg Participant either directly or indirectly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Distributions with respect to Notes held
beneficially through Clearstream Luxembourg will be credited to cash accounts of Clearstream Luxembourg Participants in accordance
with its rules and procedures to the extent received by the U.S. depositary for Clearstream Luxembourg.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><I>Euroclear</I>. Euroclear was created
in 1968 to hold securities for participants of Euroclear (&ldquo;Euroclear Participants&rdquo;) and to clear and settle transactions
between Euroclear Participants through simultaneous electronic book-entry delivery against payment, thereby eliminating the need
for physical movement of certificates and any risk from lack of simultaneous transfers of securities and cash. Euroclear includes
various other services, including securities lending and borrowing and interfaces with domestic markets in several markets in several
countries. Euroclear is operated by Euroclear Bank S.A./N.V. (the &ldquo;Euroclear Operator&rdquo;), under contract with Euroclear
Clearance Systems S.C., a Belgian cooperative corporation (the &ldquo;Cooperative&rdquo;). All operations are conducted by the
Euroclear Operator, and all Euroclear securities clearance accounts and Euroclear cash accounts are accounts with the Euroclear
Operator, not the Cooperative. The Cooperative establishes policy for Euroclear on behalf of Euroclear Participants. Euroclear
Participants include banks (including central banks), securities brokers and dealers and other professional financial intermediaries
and may include the underwriters. Indirect access to Euroclear is also available to other firms that clear through or maintain
a custodial relationship with a Euroclear Participant, either directly or indirectly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The Euroclear Operator is regulated and
examined by the Belgian Banking Commission. Distributions of principal and interest with respect to Notes held through Euroclear
or Clearstream Luxembourg will be credited to the cash accounts of Euroclear or Clearstream Luxembourg participants in accordance
with the relevant system&rsquo;s rules and procedures, to the extent received by such system&rsquo;s depositary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Links have been established among DTC,
Clearstream Luxembourg and Euroclear to facilitate the initial issuance of the Notes and cross-market transfers of the Notes associated
with secondary market trading. DTC will be linked indirectly to Clearstream Luxembourg and Euroclear through the DTC accounts of
their respective U.S. depositaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><I>Book-Entry Procedures</I>. We expect
that, pursuant to procedures established by DTC:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>upon deposit of each global note, DTC will credit, on its book-entry registration and transfer system, the accounts of participants
designated by the underwriters with an interest in that global note; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>ownership of beneficial interests in the global notes will be shown on, and the transfer of ownership interests in the global
notes will be effected only through, records maintained by DTC (with respect to the interests of participants) and by participants
and indirect participants (with respect to the interests of persons other than participants).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The laws of some jurisdictions may require
that some purchasers of Notes take physical delivery of those Notes in definitive form. Accordingly, the ability to transfer beneficial
interests in notes represented by a global note to those persons may be limited. In addition, because DTC can act only on behalf
of its participants, who in turn act on behalf of persons who hold interests through participants, the ability of a person holding
a beneficial interest in a global note to pledge or transfer that interest to persons or entities that do not participate in DTC&rsquo;s
system, or to otherwise take actions in respect of that interest, may be affected by the lack of a physical note in respect of
that interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">So long as DTC or its nominee is the
registered owner of a global note, DTC or that nominee, as the case may be, will be considered the sole legal owner or holder of
the notes represented by that global note for all purposes of the Notes and the Indenture. Except as provided below, owners of
beneficial interests in a global note (1)&nbsp;will not be entitled to have the Notes represented by that global note registered
in their names, (2)&nbsp;will not receive or be entitled to receive physical delivery of certificated notes, and (3)&nbsp;will
not be considered the owners or holders of the Notes represented by that beneficial interest under the Indenture for any purpose,
including with respect to the giving of any direction, instruction or approval to the trustee. Accordingly, each holder owning
a beneficial interest in a global note must rely on the procedures of DTC and, if that holder is not a participant or an indirect
participant, on the procedures of the participant through which that holder owns its interest, to exercise any rights of a holder
of Notes under the Indenture or that global note. We understand that under existing industry practice, in the event that we request
any action of holders of notes, or a holder that is an owner of a beneficial interest in a global note desires to take any action
that DTC, as the holder of that global note, is entitled to take, DTC would authorize the participants to take that action and
the participants would authorize holders owning through those participants to take that action or would otherwise act upon the
instruction of those holders. Neither we nor the Trustee will have any responsibility or liability for any aspect of the records
relating to or payments made on account of notes by DTC, or for maintaining, supervising or reviewing any records of DTC relating
to the Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Payments with respect to the principal
of and interest on a global note will be payable by the trustee to or at the direction of DTC or its nominee in its capacity as
the registered holder of the global note under the Indenture. Under the terms of the Indenture, we and the trustee may treat the
persons in whose names the Notes, including the global notes, are registered as the owners thereof for the purpose of receiving
payment thereon and for any and all other purposes whatsoever. Accordingly, neither we nor the trustee has or will have any responsibility
or liability for the payment of those amounts to owners of beneficial interests in a global note. Payments by the participants
and the indirect participants to the owners of beneficial interests in a global note will be governed by standing instructions
and customary industry practice and will be the responsibility of the participants and indirect participants and not of DTC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Transfers between participants in DTC
will be effected in accordance with DTC&rsquo;s procedures, and will be settled in same-day funds. Transfers between participants
in Euroclear or Clearstream Luxembourg will be effected in the ordinary way in accordance with their respective rules and operating
procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Cross-market transfers between the participants
in DTC, on the one&nbsp;hand, and Euroclear or Clearstream Luxembourg participants, on the other hand, will be effected through
DTC in accordance with DTC&rsquo;s rules on behalf of Euroclear or Clearstream Luxembourg, as the case may be, by its respective
depositary. However, those cross-market transactions will require delivery of instructions to Euroclear or Clearstream Luxembourg,
as the case may be, by the counterparty in that system in accordance with the rules and procedures and within the established deadlines
(Brussels time) of that system. Euroclear or Clearstream Luxembourg, as the case may be, will, if the transaction meets its settlement
requirements, deliver instructions to its respective depositary to take action to effect final settlement on its behalf by delivering
or receiving interests in the relevant global notes in DTC, and making or receiving payment in accordance with normal procedures
for same-day funds settlement applicable to DTC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Euroclear participants and Clearstream
Luxembourg participants may not deliver instructions directly to the depositaries for Euroclear or Clearstream Luxembourg.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Although we understand that DTC, Euroclear
and Clearstream Luxembourg have agreed to the foregoing procedures to facilitate transfers of interests in the global notes among
participants in DTC, Euroclear and Clearstream Luxembourg, they are under no obligation to perform or to continue to perform those
procedures, and those procedures may be discontinued at any time. Neither we nor the trustee will have any responsibility for the
performance by DTC, Euroclear or Clearstream Luxembourg or their respective participants or indirect participants of their respective
obligations under the rules and procedures governing their operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B><I>Same-Day Settlement and Payment</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We will make payments in respect of the
Notes represented by the global notes (including principal and interest) by wire transfer of immediately available funds to the
accounts specified by the global note holder. We will make all payments of principal and interest with respect to certificated
notes by wire transfer of immediately </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">available
funds to the accounts specified by the holders of the certificated notes or, if no such account is specified, by mailing a check
to each such holder&rsquo;s registered address. The Notes represented by the global notes are expected to trade in DTC&rsquo;s
Same-Day Funds Settlement System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Because of time zone&nbsp;differences,
the securities account of a Euroclear or Clearstream Luxembourg participant purchasing an interest in a global note from a participant
in DTC will be credited, and any such crediting will be reported to the relevant Euroclear or Clearstream Luxembourg participant,
during the securities settlement processing&nbsp;day (which must be a business&nbsp;day for Euroclear and Clearstream Luxembourg)
immediately following the settlement date of DTC. DTC has advised us that cash received in Euroclear or Clearstream Luxembourg
as a result of sales of interests in a global note by or through a Euroclear or Clearstream Luxembourg participant to a participant
in DTC will be received with value on the settlement date of DTC but will be available in the relevant Euroclear or Clearstream
Luxembourg cash account only as of the business&nbsp;day for Euroclear or Clearstream Luxembourg following DTC&rsquo;s settlement
date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">None&nbsp;of Quest Diagnostics, any underwriter
or agent, the trustee or any applicable paying agent will have any responsibility or liability for any aspect of the records relating
to or payments made on account of beneficial interests in a global note, or for maintaining, supervising or reviewing any records.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Modification or Waiver</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">There are three&nbsp;types of changes
we can make to the Indenture and the Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><I>Changes Requiring Your Approval</I>.
First, there are changes that cannot be made to your Notes without your specific approval. Following is a list of those types of
changes:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>changing the stated maturity of the principal of or interest on the Notes;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>reducing any amounts due on the Notes or payable upon acceleration of the maturity of the security following a default;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>adversely affecting any right of repayment at the holder&#8217;s option;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>changing the place (except as otherwise described in this prospectus supplement) or currency of payment on the Notes;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>impairing your right to sue for payment or to convert or exchange Notes;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>modifying the Notes to subordinate the Notes to other indebtedness;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>reducing the percentage of holders of Notes whose consent is needed to modify or amend the Indenture;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>reducing the percentage of holders of Notes whose consent is needed to waive compliance with certain provisions of the Indenture
or to waive certain defaults;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>reducing the requirements for quorum or voting with respect to the Notes;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>modifying any other aspect of the provisions of the Indenture dealing with modification and waiver except to increase the voting
requirements; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>change in any of our obligations to pay additional amounts to holders with respect to taxes imposed on such holders in certain
circumstances.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><I></I></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><I>Changes Requiring a Majority Vote</I>.
The second type of change to the Indenture and the outstanding Notes is the kind that requires a vote in favor by holders of outstanding
Notes owning a majority of the principal amount of Notes. Most changes fall into this category, except for clarifying changes and
certain other changes that would not adversely affect holders of the outstanding Notes in any material respect. The same vote would
be required for us and any domestic Subsidiary that guarantees our obligations pursuant to the terms of the Indenture to obtain
a waiver of all or part of certain covenants in the Indenture, or a waiver of a past default. However, we and any domestic Subsidiary
that guarantees our obligations pursuant to the terms of the Indenture cannot obtain a waiver of a payment default or any other
aspect of the Indenture or the outstanding Notes listed in the category described previously under &ldquo;&mdash;Changes Requiring
Your Approval&rdquo; unless we and such Subsidiary obtain your individual consent to the waiver.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><I>Changes Not Requiring Approval</I>.
The third type of change does not require any vote by holders of outstanding Notes. This type is limited to clarifications, curing
ambiguities, defects or inconsistencies and certain other changes that would not adversely affect holders of the outstanding Notes
in any material respect. Qualifying or maintaining the qualification of the Indenture under the Trust Indenture Act does not require
any vote by holders of Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Satisfaction and Discharge</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The Indenture will cease to be of further
effect, and we and our Subsidiaries that have guaranteed our obligations pursuant to the terms of the Indenture, if any, will be
deemed to have satisfied and discharged the Indenture with respect to the Notes, when the following conditions have been satisfied:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>all Notes not previously delivered to the trustee for cancellation have become due and payable or will become due and payable
at their stated maturity or on a redemption date within one&nbsp;year;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>we deposit with the trustee, in trust, funds sufficient to pay the entire indebtedness on the Notes that had not been previously
delivered for cancellation, for the principal and interest to the date of the deposit (for Notes that have become due and payable)
or to the stated maturity or the redemption date, as the case may be (for Notes that have not become due and payable);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>we have paid or caused to be paid all other sums payable under the Indenture; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>we have delivered to the trustee an Officer&#8217;s Certificate and opinion of counsel, each stating that all these conditions
have been complied with.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We will remain obligated to provide for
registration of transfer and exchange and to provide notices of redemption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>The Trustee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The trustee will be The Bank of New York
Mellon (formerly, The Bank of New York). The Bank of New York Mellon also will be the initial paying agent and registrar for the
Notes. The Bank of New York Mellon is also the trustee and note registrar for our 4.70% senior notes due 2021, our 4.25% senior
notes due 2024, our 3.45% senior notes due 2026, our 4.20% senior notes due 2029, our 2.95% senior notes due 2030, our 6.95% senior
notes due 2037, our 5.75% senior notes due 2040, our 3.50% senior notes due 2025 and our 4.70% senior notes due 2045.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The Indenture provides that, except during
the continuance of an event of default under the Indenture, the trustee under the Indenture will perform only such duties as are
specifically set forth in the Indenture. Under the Indenture, the holders of a majority in outstanding principal amount of the
Notes will have the right to direct the time, method and place of conducting any proceeding or exercising any remedy available
to the trustee under the Indenture, subject to certain exceptions. The trustee shall be under no obligation to exercise any of
the rights or powers vested in it by the Indenture at the request or direction of any of the Holders pursuant to the Indenture,
unless such Holders shall have offered to the trustee security or indemnity satisfactory to the trustee against the costs, expenses
and liabilities which might be incurred by it in compliance with such request or direction. If an </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">event
of default has occurred and is continuing, the trustee under the Indenture will exercise such rights and powers vested in it under
the Indenture and use the same degree of care and skill in its exercise as a prudent person would exercise under the circumstances
in the conduct of such person&rsquo;s own affairs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The Indenture and provisions of the Trust
Indenture Act incorporated by reference in the Indenture contain limitations on the rights of the trustee under such Indenture,
should it become a creditor of our company, to obtain payment of claims in certain cases or to realize on certain property received
by it in respect of any such claims, as security or otherwise. The trustee under the Indenture is permitted to engage in other
transactions. However, if the trustee under the Indenture acquires any prohibited conflicting interest, it must eliminate the conflict
or resign.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The trustee may resign or be removed
and a successor trustee may be appointed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Governing Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The Indenture and the Notes will be governed
by, and construed in accordance with, the laws of the State of New York without application of principles of conflicts of law thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Definitions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The following definitions are applicable
to this Description of Notes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Acquired Indebtedness&rdquo; means
Indebtedness of a Person (1)&nbsp;existing at the time such Person becomes a Restricted Subsidiary or (2)&nbsp;assumed in connection
with the acquisition of assets by such Person, in each case, other than Indebtedness incurred in connection with, or in contemplation
of, such Person becoming a Restricted Subsidiary or such acquisition, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Attributable Debt&rdquo; means,
with respect to a Sale and Leaseback Transaction, an amount equal to the lesser of: (1)&nbsp;the fair market value of the property
(as determined in good faith by our board of directors); and (2)&nbsp;the present value of the total net amount of rent payments
to be made under the lease during its remaining term, discounted at the rate of interest set forth or implicit in the terms of
the lease, compounded semiannually. The calculation of the present value of the total net amount of rent payments is subject to
adjustments specified in the Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Capitalized Lease&rdquo; means
any obligation of a Person to pay rent or other amounts incurred with respect to real property or equipment acquired or leased
by such Person and used in its business that is required to be recorded as a capital lease in accordance with generally accepted
accounting principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Consolidated Total Assets&rdquo;
means, with respect to any Person as of any date, the amount of total assets as shown on the consolidated balance sheet of such
Person for the most recent fiscal quarter for which financial statements have been filed with the Securities and Exchange Commission,
prepared in accordance with accounting principles generally accepted in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Existing Receivables Credit Facility&rdquo;
means the receivables-backed financing transaction pursuant to (1)&nbsp;the Fourth Amended and Restated Receivables Sale Agreement,
dated as of October&nbsp;28, 2015 between Quest Diagnostics and each of its direct and indirect wholly owned Subsidiaries that
is a seller thereunder, and Quest Diagnostics Receivables Inc., as the buyer, as amended (2)&nbsp;the Sixth Amended and Restated
Credit and Security Agreement, dated as of October&nbsp;27, 2017, among Quest Diagnostics Receivables Inc., as borrower, Quest
Diagnostics, as initial servicer, each of the lenders from time to time party thereto, and The Bank of Tokyo-Mitsubishi UFJ, Ltd.,
New York Branch, as administrative agent, as amended and (3)&nbsp;the various related ancillary documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Indebtedness&rdquo; of any Person
means, without duplication (1)&nbsp;any obligation of such Person for money borrowed, (2)&nbsp;any obligation of such Person evidenced
by bonds, debentures, notes or other similar instruments, (3)&nbsp;any reimbursement obligation of such Person in respect of letters
of credit or other similar instruments which support financial obligations which would otherwise become Indebtedness, and (4)&nbsp;any
obligation of such Person</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 0pt; text-align: justify">under
Capitalized Leases; <I>provided</I>, <I>however</I>, that &ldquo;Indebtedness&rdquo; of such Person shall not include any obligation
of such Person to any Subsidiary of such Person or to any Person with respect to which such Person is a Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Lien&rdquo; means any pledge,
mortgage, lien, encumbrance or other security interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Officer&rsquo;s Certificate&rdquo;
means a certificate signed by any Officer of Quest Diagnostics or any domestic Subsidiary that guarantees the obligations of Quest
Diagnostics pursuant to the terms of the Indenture, as the case may be, in his or her capacity as such Officer and delivered to
the trustee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Permitted Acquired Indebtedness&rdquo;
means any Acquired Indebtedness that remains outstanding following the expiration of a good faith offer by Quest Diagnostics or
the Subsidiary of Quest Diagnostics obligated under such Acquired Indebtedness to acquire such Acquired Indebtedness, including,
without limitation, an offer to exchange such Acquired Indebtedness for debt securities of Quest Diagnostics, on terms, which in
the opinion of an independent investment banking firm of national reputation and standing, are consistent with market practices
in existence at the time for offers of a similar nature; <I>provided</I> that the initial expiration date of any such offer shall
be not later than the expiration of the 270-day period referred to in the first paragraph of the &ldquo;&mdash;Limitation on Subsidiary
Indebtedness and Preferred Stock&rdquo; covenant<I>; provided further</I> that the amount of Acquired Indebtedness that shall constitute
&ldquo;Permitted Acquired Indebtedness&rdquo; shall only be equal to the amount of Acquired Indebtedness that Quest Diagnostics
or such Subsidiary has made an offer to acquire in accordance with the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Person&rdquo; means any individual,
corporation, limited liability company, partnership, joint venture, association, joint stock company, trust, unincorporated organization
or government or any agency or political subdivision thereof or other similar entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Preferred Stock&rdquo; means,
with respect to any Person, any and all shares of preferred stock (however designated) issued by such Person, that is entitled
to preference or priority over one&nbsp;or more series or classes of capital stock issued by such Person upon any distribution
of such Person&rsquo;s property and assets, whether by dividend or on liquidation, whether now outstanding, or issued after the
date that the Notes are issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Principal Property&rdquo; means
any real property and any related buildings, fixtures or other improvements located in the United States owned by Quest Diagnostics
or its Subsidiaries (1)&nbsp;on or in which one&nbsp;of its 30 largest domestic clinical laboratories conducts operations, as determined
by net revenues for the four&nbsp;most recent fiscal quarters for which financial statements have been filed with the Securities
and Exchange Commission, or (2)&nbsp;the net book value of which at the time of the determination exceeds 1% of the Consolidated
Total Assets of Quest Diagnostics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Receivables Credit Facility&rdquo;
means any receivables-backed financing transaction including the Existing Receivables Credit Facility, in each case as such transaction
may be amended or otherwise modified from time to time or refinanced or replaced with respect to all or any portion of the indebtedness
under such transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Restricted Subsidiary&rdquo; means
any Subsidiary of Quest Diagnostics that owns a Principal Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Sale and Leaseback Transaction&rdquo;
means any arrangement with any person providing for the leasing by Quest Diagnostics or any Restricted Subsidiary of any Principal
Property that has been or is to be sold or transferred by Quest Diagnostics or any Restricted Subsidiary to such person, as the
case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Subsidiary&rdquo; of any Person
means (1)&nbsp;a corporation, a majority of the outstanding voting stock of which is, at the time, directly or indirectly, owned
by such Person by one&nbsp;or more Subsidiaries of such Person, or by such Person and one&nbsp;or more Subsidiaries thereof or
(2)&nbsp;any other Person (other than a corporation), including, without limitation, a partnership or joint venture, in which such
Person, one&nbsp;or more Subsidiaries thereof or such Person and one&nbsp;or more Subsidiaries thereof, directly or indirectly,
at the date of determination thereof, has at least majority ownership interest entitled to vote in the election of directors, managers
or trustees thereof (or other Person performing similar functions).<BR STYLE="clear: both">
</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="UnitedStatesFederal" TITLE="UnitedStatesFederal"></A>UNITED
STATES FEDERAL INCOME TAX CONSIDERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The following discussion is a summary
of the material U.S. federal income tax consequences relevant to the purchase, ownership and disposition of the notes, but does
not purport to be a complete analysis of all potential tax effects. The discussion is based upon the Internal Revenue Code of 1986,
as amended (the &ldquo;Code&rdquo;), U.S. Treasury regulations issued thereunder, Internal Revenue Service (&ldquo;IRS&rdquo;)
rulings and pronouncements and judicial decisions now in effect, all of which are subject to change at any time. Any such change
may be applied retroactively in a manner that could adversely affect a beneficial owner of the notes. This discussion does not
address alternative minimum tax consequences, U.S. federal estate or gift tax laws, the Medicare tax on net investment income or
all of the U.S. federal income tax consequences that may be relevant to a beneficial owner of the notes in light of such beneficial
owner&rsquo;s particular circumstances or to beneficial owners of the notes subject to special rules, such as financial institutions,
U.S. expatriates, insurance companies, dealers in securities or foreign currencies, traders in securities, &ldquo;U.S. Holders&rdquo;
(as defined below) whose functional currency is not the U.S. dollar, partnerships and other pass-through entities and their beneficial
owners, tax-exempt organizations or accounts and persons holding the notes as part of a &ldquo;straddle,&rdquo; &ldquo;hedge,&rdquo;
&ldquo;conversion transaction&rdquo; or other integrated transaction. In addition, this discussion is limited to beneficial owners
of notes that purchase notes for cash in this offering at a price equal to their &ldquo;issue price&rdquo; within the meaning of
Section&nbsp;1273 of the Code (i.e. the first price at which a substantial amount of the notes is sold to the public for cash),
and that hold the notes as &ldquo;capital assets&rdquo; within the meaning of Section&nbsp;1221 of the Code (generally, property
held for investment). Moreover, the effect of any applicable state, local or foreign tax laws, and any part of U.S. federal tax
law other than law pertaining to income taxation, is not discussed in this summary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">As used in this prospectus supplement,
&ldquo;U.S. Holder&rdquo; means a beneficial owner of the notes that is for U.S. federal income tax purposes:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>an individual who is a citizen or resident of the United States;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>a corporation (or other entity taxable as a corporation) created or organized in or under the laws of the United States, any
state thereof or the District of Columbia;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>an estate, the income of which is subject to U.S. federal income tax regardless of its source; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>a trust, if a U.S. court can exercise primary supervision over the administration of the trust and one&nbsp;or more U.S. persons
can control all substantial trust decisions, or if the trust was in existence on August&nbsp;20, 1996 and has elected to continue
to be treated as a U.S. person.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">A &ldquo;non-U.S. Holder&rdquo; is a
beneficial owner of notes that is neither a U.S. Holder nor a partnership (or other entity or arrangement treated as a partnership)
for U.S. federal income tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">If a beneficial owner of the notes is
a partnership or other entity or arrangement treated as a partnership for U.S. federal income tax purposes, the tax treatment of
the partnership and each partner in such partnership generally will depend on the activities of the partnership, the status of
the partner and certain determinations made at the partner level. Partnerships that hold notes, and partners in such partnerships,
should consult their own tax advisors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Prospective investors should consult
their own tax advisors with regard to the application of the tax consequences discussed below to their particular situations as
well as the application of any state, local, foreign or other tax laws, including gift and estate tax laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Characterization of the Notes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Under certain circumstances, the notes
provide for payments in excess of stated interest and principal and/or redemption prior to their stated maturity. We intend to
take the position that these provisions will not cause the notes to be subject to the contingent payment debt instrument rules
of applicable U.S. Treasury Regulations (the &ldquo;CPDI Rules&rdquo;). Our position is binding on a holder, unless the holder
discloses in the proper manner to the IRS that it is taking a different position. Our position is not, however, binding on the
IRS. If the IRS successfully challenged </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B></B></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">our position, the tax consequences of owning and disposing of the notes could be materially
different than those described herein, including with respect to the character, timing and amount of income, gain or loss recognized.
The remainder of this discussion assumes that the notes are not subject to the CPDI Rules, but there can be no assurances in this
regard. Holders are urged to consult their own tax advisors regarding the potential application to the notes of the CPDI Rules
and the consequences thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>U.S. Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><I>Payment of Stated Interest</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Payments of stated interest on the notes
generally will be taxable to a U.S. Holder as ordinary income at the time that such payments are received or accrued, in accordance
with such U.S. Holder&rsquo;s regular method of accounting for U.S. federal income tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><I>Sale or Other Taxable Disposition
of the Notes</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">A U.S. Holder will recognize gain or
loss on the sale, exchange, redemption, retirement or other taxable disposition of a note in an amount equal to the difference
between the amount realized upon the disposition (less any portion allocable to any accrued and unpaid stated interest, which will
be taxable as ordinary interest income to the extent not previously included in gross income) and the U.S. Holder&rsquo;s tax basis
in the note. A U.S. Holder&rsquo;s tax basis in a note generally will be the price such U.S. Holder paid for the note. Such gain
or loss generally will be a capital gain or loss, and will be a long-term capital gain or loss if the U.S. Holder has held the
note for more than one&nbsp;year at the time of the disposition. Non-corporate U.S. Holders may be eligible for reduced rates of
U.S. federal income tax on long-term capital gains. The deductibility of capital losses is subject to limitations under the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><I>Backup Withholding and Information
Reporting</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">In general, information reporting requirements
will apply to payments of interest on the notes and to the proceeds of the sale or other disposition (including a retirement or
redemption) of a note paid to a U.S. Holder unless such U.S. Holder is an exempt recipient and, when required, provides evidence
of such exemption. In addition, a U.S. Holder may be subject to backup withholding on such payments. Certain U.S. Holders (including,
among others, corporations and certain tax-exempt organizations) generally are exempt from backup withholding, but may be required
to certify to their exempt status. A non-exempt U.S. Holder will be subject to backup withholding if such U.S. Holder:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>fails to furnish its taxpayer identification number (&#8220;TIN&#8221;), which, for an individual, ordinarily is his or her
social security number;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>furnishes an incorrect TIN;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>is notified by the IRS that the U.S. Holder has failed to properly report payments of interest or dividends; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>fails to certify, under penalties of perjury, that the U.S. Holder is a U.S. person, has furnished a correct TIN and that the
IRS has not notified the U.S. Holder that it is subject to backup withholding.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">U.S. Holders should consult their own
tax advisors regarding their qualification for an exemption from backup withholding and the procedures for obtaining such an exemption,
if applicable. The backup withholding tax is not an additional tax and U.S. Holders may use amounts withheld as a credit against
their U.S. federal income tax liability or such amounts may be refunded to the U.S. Holder so long as the requisite information
is timely furnished to the IRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Non-U.S. Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><I>Payment of Stated Interest</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Subject to the discussions below regarding
backup withholding and FATCA (as defined below), interest paid to a non-U.S. Holder generally will not be subject to U.S. federal
income tax or U.S. federal withholding tax of 30% (or, if applicable, a lower treaty rate), provided:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>such non-U.S. Holder does not directly or indirectly, actually or constructively, own 10% or more of the total combined voting
power of all of our classes of stock;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>such non-U.S. Holder is not a controlled foreign corporation that is related to us through sufficient direct or indirect stock
ownership;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>such interest is not effectively connected with a trade or business conducted by the non-U.S. Holder within the United States;
and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>(1) the non-U.S. Holder provides the applicable withholding agent with a properly completed IRS Form&nbsp;W-8BEN or W-8BEN-E
(or other applicable form), which includes its name and address and a certification, under penalties of perjury, that the non-U.S.
Holder is not a &#8220;United States person&#8221; within the meaning of the Code, or (2)&nbsp;a securities clearing organization,
bank or other financial institution that holds customers&#8217; securities in the ordinary course of its trade or business and
holds the notes on behalf of the non-U.S. Holder certifies to the applicable withholding agent under penalties of perjury that
it, or the financial institution between it and the non-U.S. Holder, has received from the non-U.S. Holder a properly completed
IRS Form&nbsp;W-8BEN or W-8BEN-E (or other applicable form), which includes a statement, under penalties of perjury, that such
non-U.S. Holder is not a &#8220;United States person&#8221; and provides the applicable withholding agent with a copy of this statement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">If a non-U.S. Holder cannot satisfy the
requirements described above, payments of interest made to the non-U.S. Holder will be subject to the 30% U.S. federal withholding
tax, unless the non-U.S. Holder provides the applicable withholding agent with a properly executed (1)&nbsp;IRS Form&nbsp;W-8BEN
or W-8BEN-E (or other applicable form) claiming an exemption from or reduction in withholding under the benefit of an applicable
tax treaty or (2)&nbsp;IRS Form&nbsp;W-8ECI (or other applicable form) stating that interest paid on the notes is not subject to
withholding tax because it is effectively connected with such non-U.S. Holder&rsquo;s conduct of a trade or business in the United
States, in which case the non-U.S. Holder generally will be subject to tax on a net basis on payments of interest made to the non-U.S.
Holder in the same manner as a U.S. Holder, as described below in the second paragraph under &ldquo;&mdash;Sale or Other Taxable
Disposition of the Notes.&rdquo; Prospective investors should consult their tax advisors regarding the certification requirements
for non-U.S. Holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><I>Sale or Other Taxable Disposition
of the Notes</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Subject to the discussion below regarding
backup withholding, a non-U.S. Holder generally will not be subject to U.S. federal income tax or withholding tax on gain and any
accrued interest recognized on the sale, exchange, redemption, retirement or other disposition of a note unless (1)&nbsp;such gain
is effectively connected with a trade or business conducted by the non-U.S. Holder within the United States (and, if required by
an applicable income tax treaty, is attributable to a U.S. &ldquo;permanent establishment&rdquo; maintained by the non-U.S. Holder),
(2)&nbsp;such non-U.S. Holder is an individual who was present in the United States for 183&nbsp;days or more in the taxable&nbsp;year
of the disposition and certain other conditions are met (in which case, except as otherwise provided by an applicable income tax
treaty, such gain, which may be offset by U.S. source capital losses, generally will be subject to a flat 30% U.S. federal income
tax, even though the non-U.S. Holder is not considered a resident alien under the Code) or (3)&nbsp;in the case of accrued interest,
such accrued interest does not qualify for the exemption from U.S. federal income tax and U.S. federal withholding tax discussed
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">If interest on the notes or gain from
a disposition of the notes is effectively connected with a non-U.S. Holder&rsquo;s conduct of a U.S. trade or business (and, if
required by an applicable income tax treaty, is attributable to a U.S. &ldquo;permanent establishment&rdquo; maintained by the
non-U.S. Holder), the non-U.S. Holder generally will be subject to U.S. federal income tax on the interest or gain on a net basis
in the same manner as U.S. Holders. For effectively-connected interest, the 30% withholding tax described above will not apply
(assuming an appropriate certification is timely provided by the non-U.S. Holder). A foreign corporation that is a non-U.S. Holder
of a note also may be subject to a branch profits tax equal to 30% of its effectively connected earnings and profits for the taxable&nbsp;year,
subject to certain adjustments, unless it qualifies for a lower rate under an applicable income tax treaty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><I>Backup Withholding and Information
Reporting</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Backup withholding and information reporting
generally will not apply to payments to a non-U.S. Holder of a note if the non-U.S. Holder has provided the applicable withholding
agent with the required certification that it is not a U.S. person as described above in &ldquo;&mdash;Payment of Stated Interest,&rdquo;
<I>provided</I> that the applicable withholding agent does not have actual knowledge or reason to know that the non-U.S. Holder
is a U.S. person. However, the applicable withholding agent may be required to report to the IRS and to non-U.S. Holders payments
of interest on the notes and the amount of tax, if any, withheld with respect to those payments. Copies of the information returns
reporting such interest payments and any withholding may also be made available to the tax authorities in the country in which
such non-U.S. Holders reside under the provisions of a treaty or agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">If a non-U.S. Holder sells a note outside
the United States through a non-U.S. office of a non-U.S. broker and the sales proceeds are paid to the non-U.S. Holder outside
the United States, then backup withholding and information reporting generally will not apply to that payment. However, information
reporting, but not backup withholding, will apply to a payment of sales proceeds, even if that payment is made outside the United
States, if a non-U.S. Holder sells a note through a non-U.S. office of a broker with certain U.S. connections, unless such broker
has documentary evidence in its possession of the required certification of the non-U.S. Holder&rsquo;s foreign status as described
above and has no knowledge or reason to know to the contrary, or the non-U.S. Holder otherwise establishes an exemption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Payment of the proceeds from a disposition
by a non-U.S. Holder of a note made to or through the U.S. office of a broker generally will be subject to information reporting
and backup withholding unless the non-U.S. Holder certifies that it is not a &ldquo;United States person&rdquo; or otherwise establishes
an exemption from information reporting and backup withholding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Non-U.S. Holders should consult their
own tax advisors regarding application of backup withholding in their particular circumstance and the availability of any procedure
for obtaining an exemption from backup withholding under current Treasury regulations. Any amounts withheld under the backup withholding
rules from a payment to a non-U.S. Holder will be allowed as a credit against the non-U.S. Holder&rsquo;s U.S. federal income tax
liability or such amounts may be refunded to the non-U.S. Holder, <I>provided</I> the required information is timely furnished
to the IRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Foreign Account Tax Compliance Act</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The Foreign Account Tax Compliance Act
and Treasury regulations thereunder, commonly referred to as &ldquo;FATCA,&rdquo; impose a U.S. federal withholding tax of 30%
on certain types of payments, including payments of U.S. source interest (such as interest on the notes), made to beneficial owners
or intermediaries that are (i)&nbsp;&ldquo;foreign financial institutions&rdquo; unless they agree to collect and disclose to the
IRS information regarding their direct and indirect U.S. account holders and comply with certain other requirements and (ii)&nbsp;certain
non-financial foreign entities unless they satisfy certain information reporting requirements regarding their direct and indirect
U.S. owners. Accordingly, the entity through which a U.S. Holder or a non-U.S. Holder holds its notes will affect the determination
of whether such withholding is required. Foreign financial institutions located in jurisdictions that have an intergovernmental
agreement in place with the United States with respect to FATCA may be subject to modified rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We will not pay any additional amounts
to U.S. Holders or Non-U.S. Holders in respect of any amounts withheld under FATCA. You are urged to consult your own tax advisor
regarding FATCA and the application of these requirements to your investment in the notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><BR STYLE="clear: both">
</P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><A NAME="Underwriting" TITLE="Underwriting"></A><FONT STYLE="font-size: 10pt"><B>UNDERWRITING
(CONFLICTS OF INTEREST)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Under the terms and subject to the conditions
contained in an underwriting agreement dated the date of this prospectus supplement, the underwriters named below for whom Goldman
Sachs &amp; Co. LLC, J.P. Morgan Securities LLC and Mizuho Securities USA LLC are acting as representatives and have severally
agreed to purchase, and we have agreed to sell to them, severally, the principal amount of notes indicated in the table below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Underwriter</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Principal Amount of Notes</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left; text-indent: -8.05pt; padding-left: 8.05pt">Goldman Sachs &amp; Co. LLC&#9;</TD><TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">118,250,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.05pt; padding-left: 8.05pt">J.P. Morgan Securities LLC&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">118,250,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.05pt; padding-left: 8.05pt">Mizuho Securities USA LLC&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">118,250,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.05pt; padding-left: 8.05pt">Morgan Stanley &amp; Co. LLC&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.05pt; padding-left: 8.05pt">Wells Fargo Securities, LLC&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.05pt; padding-left: 8.05pt">Credit Agricole Securities (USA) Inc.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,375,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.05pt; padding-left: 8.05pt">MUFG Securities Americas Inc.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,625,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.05pt; padding-left: 8.05pt">Fifth Third Securities, Inc.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,750,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.05pt; padding-left: 8.05pt">PNC Capital Markets LLC</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,750,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.05pt; padding-left: 8.05pt">BNY Mellon Capital Markets, LLC</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,250,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.05pt; padding-left: 8.05pt">BofA Securities, Inc.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,250,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.05pt; padding-left: 8.05pt">KeyBanc Capital Markets Inc.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,250,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt; text-indent: -8.05pt; padding-left: 8.05pt">Total&#9;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">&nbsp;&nbsp;550,000,000</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The underwriters are offering the notes
subject to their acceptance of the notes from us and subject to prior sale. The underwriting agreement provides that the obligations
of the several underwriters to pay for and accept delivery of the notes offered by this prospectus supplement are subject to the
approval of certain legal matters by their counsel and to certain other conditions. The underwriters are obligated to take and
pay for all the notes offered by this prospectus supplement if any such notes are taken. The offering of the notes by the underwriters
is subject to receipt and acceptance and subject to the underwriters&rsquo; right to reject any order in whole or in part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The underwriters initially propose
to offer part of the notes directly to the public at the public offering prices set forth on the cover page&nbsp;of this
prospectus supplement and part to certain dealers at a price that represents a concession not in excess of 0.39% of the
principal amount of the notes. Any such dealers may resell any notes purchased from the underwriters to certain other brokers
or dealers at a discount not to exceed 0.25% of the principal amount of the notes. After the initial offering of the notes, the
offering price and other selling terms may from time to time be varied by the representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The following table shows the per note
and total public offering price, underwriting discount and proceeds before expenses to us:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Per Note</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Total</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left; text-indent: -8.05pt; padding-left: 8.05pt">Public offering price<SUP>(1)</SUP>&#9;</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">99.854</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">549,197,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -8.05pt; padding-left: 8.05pt">Underwriting discount&#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.650</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,575,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -8.05pt; padding-left: 8.05pt">Proceeds, before expenses, to us &#9;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">99.204</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">545,622,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 1pt 5.5in 1pt 0in; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 0.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 1pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>Plus accrued interest from May 13, 2020, if settlement occurs after that date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The estimated offering expenses payable
by us, exclusive of the underwriting discount, are approximately $2 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">In order to facilitate the offering of
the notes, the underwriters may engage in transactions that stabilize, maintain or otherwise affect the prices of the notes. Specifically,
the underwriters may over-allot in connection with the offering, creating short positions in the notes for their own account. In
addition, to cover over-allotments or to stabilize the prices of the notes, the underwriters may bid for and purchase notes on
the open market. Further, the underwriting syndicate may reclaim selling concessions allowed to an underwriter or a dealer for
distributing the notes in the offering, if the syndicate repurchases previously distributed notes in transactions to cover syndicate</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">short positions, in stabilization transactions or otherwise. Any of these activities may stabilize or maintain the market price
of the notes above independent market levels. The underwriters are not required to engage in these activities, and may end any
of these activities at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We have agreed to indemnify the several
underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Prior to the offering, there have been
no active markets for the notes. The underwriters have advised us that certain of the underwriters presently intend to make markets
in the notes as permitted by applicable laws and regulations. Such underwriters are not obligated, however, to make the markets
in the notes and any such market making may be discontinued at any time at the discretion of such underwriters. Accordingly, no
assurance can be given as to the liquidity of, or trading markets for, the notes. We do not intend to apply for listing of the
notes on any securities exchange or for the inclusion of the notes in any automated quotation system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The underwriters also may impose a penalty
bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting discount received by it
because the representatives have repurchased notes sold by or for the account of such underwriter in stabilizing or short-covering
transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The underwriters and their
respective affiliates are full service financial institutions engaged in various activities, which may include securities
trading, commercial and investment banking, financial advisory, investment management, investment research, principal
investment, hedging, financing, corporate trust and brokerage activities. Certain of the underwriters and their respective
affiliates have, from time to time, performed, and may in the future perform, various financial advisory, investment banking
and commercial banking services for our company, for which they received or will receive customary fees and expenses. The
underwriters of the notes offered hereby served as underwriters for our offering of notes in December 2019. In addition,
affiliates of certain of the underwriters are lenders under our secured receivables credit facility and our senior unsecured
revolving credit facility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">In the ordinary course of their various
business activities, the underwriters and their respective affiliates have made or held, and may in the future make or hold, a
broad array of investments including serving as counterparties to certain derivative and hedging arrangements, and may have actively
traded, and, in the future may actively trade, debt and equity securities (or related derivative securities), and financial instruments
(including bank loans) for their own account and for the accounts of their customers and may have in the past and at any time in
the future hold long and short positions in such securities and instruments. The underwriters and their respective affiliates may
also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research
views in respect of such securities or instruments and may at any time hold, or recommend to clients that they should acquire,
long and/or short positions in such securities and instruments. Such investment and securities activities may have involved, and
in the future may involve, securities and instruments of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><B>Conflicts of Interest</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">As described in &ldquo;Use of Proceeds&rdquo;
in this prospectus supplement, we expect to use the net proceeds from this offering for general corporate purposes, which may
include the redemption or repayment of indebtedness, including our 4.70% Senior Notes and our outstanding borrowings under our
senior unsecured revolving credit facility and our secured receivables credit facility. Certain of the underwriters (or their
affiliates) may hold the 4.70% Senior Notes and would receive a portion of the proceeds from this offering if such notes were
to be redeemed or repaid. In addition, certain of the underwriters (or their affiliates) may be lenders under our senior unsecured
revolving credit facility or our secured receivables credit facility and would receive a portion of the proceeds from this offering
if outstanding borrowings under our credit facilities were to be repaid. If any one underwriter, together with its affiliates,
were to receive 5% or more of the net proceeds of this offering by reason of the redemption or repayment, such underwriters would
be deemed to have a &ldquo;conflict of interest&rdquo; within the meaning of Rule 5121. Accordingly, this offering will be conducted
in accordance with Rule 5121. No underwriter with a &ldquo;conflict of interest&rdquo; under Rule 5121 will confirm sales to any
account over which it exercises discretion without the specific written approval of the account holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Selling Restrictions </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Notice to Prospective Investors in the European Economic
Area and the United Kingdom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The notes are not intended to be offered,
sold or otherwise made available to and should not be offered, sold or otherwise made available to any retail investor in the
European Economic Area (&ldquo;EEA&rdquo;) or in the United Kingdom (&ldquo;UK&rdquo;). For these purposes, (a) a retail investor
means a person who is one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU (as
amended, &ldquo;MiFID II&rdquo;); or (ii) a customer within the meaning of Directive 2002/92/EC, where that customer would not
qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II; or (iii) not a qualified investor as defined
in Directive 2003/71/EC and (b) the expression &ldquo;offer&rdquo; includes the communication in any form and by any means of
sufficient information on the terms of the offer and the notes to be offered so as to enable an investor to decide to purchase
or subscribe the notes. . Consequently no key information document required by Regulation (EU) No 1286/2014 (as amended, the &ldquo;PRIIPs
Regulation&rdquo;) for offering or selling the notes or otherwise making them available to retail investors in the EEA or in the
UK has been prepared and therefore offering or selling the notes or otherwise making them available to any retail investor in
the EEA or in the UK may be unlawful under the PRIIPS Regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-indent: 30.6pt">This prospectus supplement has been
prepared on the basis that any offer of notes in any member state of the EEA or in the UK will be made pursuant to an exemption
under the Prospectus Regulation from the requirement to publish a prospectus for offers of the notes. This prospectus supplement
is not a prospectus for the purposes of the Prospectus Regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Notice to Prospective Investors in the United Kingdom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0pt; text-indent: 0.5in">The notes may not be offered in the
United Kingdom other than by an underwriter that (i)&nbsp;has only communicated or caused to be communicated, and will only communicate
or cause to be communicated, an invitation or inducement to engage in investment activity (within the meaning of Section&nbsp;21
of the Financial Services and Markets Act 2000 (the &ldquo;FSMA&rdquo;)) received by it in connection with the issue or sale of
the notes in circumstances in which Section&nbsp;21(1) of the FSMA does not apply to the Company; and (ii)&nbsp;has complied and
will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the notes in, from or
otherwise involving the United Kingdom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Notice to Prospective Investors in Hong Kong</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The notes may not be offered or sold
by means of any document other than (i)&nbsp;in circumstances which do not constitute an offer to the public within the meaning
of the Companies Ordinance (Cap.32, Laws of Hong Kong), or (ii)&nbsp;to &ldquo;professional investors&rdquo; within the meaning
of the Securities and Futures Ordinance (Cap.571, Laws of Hong Kong) and any rules made thereunder, or (iii)&nbsp;in other circumstances
which do not result in the document being a &ldquo;prospectus&rdquo; within the meaning of the Companies Ordinance (Cap.32, Laws
of Hong Kong), and no advertisement, invitation or document relating to the notes may be issued or may be in the possession of
any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of
which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the laws of Hong Kong)
other than with respect to notes which are or are intended to be disposed of only to persons outside Hong Kong or only to &ldquo;professional
investors&rdquo; within the meaning of the Securities and Futures Ordinance (Cap.571, Laws of Hong Kong) and any rules made thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Notice to Prospective Investors in Japan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The notes have not been and will not
be registered under the Financial Instruments and Exchange Law of Japan (the Financial Instruments and Exchange Law) and each
underwriter has agreed that it will not offer or sell any notes, directly or indirectly, in Japan or to, or for the benefit of,
any resident of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity
organized under the laws of Japan), or to others for re-offering or resale, directly or indirectly, in Japan or to a resident
of Japan, except pursuant to an</P>




<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">exemption from the registration requirements of, and otherwise in compliance with, the Financial
Instruments and Exchange Law and any other applicable laws, regulations and ministerial guidelines of Japan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Notice to Prospective Investors in Singapore</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">This prospectus has not been registered
as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection
with the offer or sale, or invitation for subscription or purchase, of the notes may not be circulated or distributed, nor may
the notes be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly,
to persons in Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act,
Chapter&nbsp;289 of Singapore (the &ldquo;SFA&rdquo;), (ii)&nbsp;to a relevant person, or any person pursuant to Section&nbsp;275(1A),
and in accordance with the conditions, specified in Section&nbsp;275 of the SFA or (iii)&nbsp;otherwise pursuant to, and in accordance
with the conditions of, any other applicable provision of the SFA. Solely for the purposes of its obligations pursuant to Sections
309B(1)(a) and 309B(1)(c) of the SFA, the Company has determined, and hereby notifies all relevant persons (as defined in Section
309A of the SFA) that the notes are &ldquo;prescribed capital markets products&rdquo; (as defined in the Securities and Futures
(Capital Markets Products) Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA 04-N12: Notice on the
Sale of Investment Products and MAS Notice FAA-N16: Notice on Recommendations on Investment Products).</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Where the notes are subscribed or purchased
under Section&nbsp;275 by a relevant person which is: (a)&nbsp;a corporation (which is not an accredited investor) the sole business
of which is to hold investments and the entire share capital of which is owned by one&nbsp;or more individuals, each of whom is
an accredited investor; or (b)&nbsp;a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments
and each beneficiary is an accredited investor, shares, debentures and units of shares and debentures of that corporation or the
beneficiaries&rsquo; rights and interest in that trust shall not be transferable for 6&nbsp;months after that corporation or that
trust has acquired the notes under Section&nbsp;275 except: (1)&nbsp;to an institutional investor under Section&nbsp;274 of the
SFA or to a relevant person, or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions, specified in
Section&nbsp;275 of the SFA; (2)&nbsp;where no consideration is given for the transfer; or (3)&nbsp;by operation of law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Notice to Prospective Investors in Canada</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The notes may be sold in Canada only
to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument
45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National
Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the notes must be made
in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities
laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Securities legislation in certain provinces
or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment
thereto) contains a misrepresentation, <I>provided</I> that the remedies for rescission or damages are exercised by the purchaser
within the time limit prescribed by the securities legislation of the purchaser&rsquo;s province or territory. The purchaser should
refer to any applicable provisions of the securities legislation of the purchaser&rsquo;s province or territory for particulars
of these rights or consult with a legal advisor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Pursuant to section 3A.3 of National
Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the disclosure requirements
of NI 33-105 regarding underwriter conflicts of interest in connection with this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 10pt"><A NAME="LegalMatters" TITLE="LegalMatters"></A><B>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Certain legal matters in connection with
the notes offered hereby will be passed upon for us by Shearman &amp; Sterling LLP, New York, New York. Certain legal matters in
connection with the notes offered hereby will be passed upon for the underwriters by Fried, Frank, Harris, Shriver &amp; Jacobson
LLP, New York, New York.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><A NAME="Experts" TITLE="Experts"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The financial statements and management&rsquo;s
assessment of the effectiveness of internal control over financial reporting (which is included in the Report of Management on
Internal Control over Financial Reporting) incorporated in this prospectus supplement by reference to the Annual Report on Form&nbsp;10-K
for the&nbsp;year ended December&nbsp;31, 2019, have been so incorporated in reliance on the report of PricewaterhouseCoopers LLP,
an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 10pt"><A NAME="WhereYouCanFind" TITLE="WhereYouCanFind"></A><B>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We file annual, quarterly and special
reports, proxy statements and other information with the SEC. Our filings are also available to the public on the Internet, through
a database maintained by the SEC at http://www.sec.gov. In addition, you can inspect and copy our reports, proxy statements and
other information at the offices of The New York Stock Exchange, 11 Wall Street, New York, New York 10005.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The SEC allows us to incorporate by reference
into this document the information we filed with it. This means that we can disclose important business, financial and other information
to you by referring you to other documents separately filed with the SEC. All information incorporated by reference is part of
this document, unless and until that information is updated and superseded by the information contained in this document or any
information incorporated later.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We incorporate by reference the documents
listed below (except for information furnished to the SEC that is not deemed to be &ldquo;filed&rdquo; for purposes of the Securities
Exchange Act of 1934, or the Exchange Act):</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.</TD><TD>Our Annual Report on Form 10-K for the fiscal year ended <A HREF="http://www.sec.gov/Archives/edgar/data/1022079/000102207920000017/dgx1231201910-k.htm">December 31, 2019</A>;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.</TD><TD>Our Quarterly Report on Form 10-Q for the quarter ended <A HREF="http://www.sec.gov/Archives/edgar/data/1022079/000102207920000107/dgx0331202010-q.htm">March 31, 2020</A>;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.</TD><TD>Our proxy statement on Schedule 14A filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1022079/000094787120000354/ss170887_def14a.htm">April 8, 2020</A>; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: left">Our Current Reports on Form 8-K, filed on <A HREF="http://www.sec.gov/Archives/edgar/data/1022079/000102207920000083/dgx0312208-k.htm">March 16, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1022079/000102207920000091/dgx0331208-k.htm">March 31, 2020</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1022079/000094787120000426/ss171981_8k.htm">May 4, 2020</A>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The above list of documents that we are
incorporating by reference into this document amends and supersedes the list of documents included in the &ldquo;Where You Can
Find More Information&rdquo; section of the accompanying prospectus in its entirety.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Our filings with the SEC, including our
Annual Report on Form&nbsp;10-K, Quarterly Reports on Form&nbsp;10-Q, current reports on Form&nbsp;8-K and amendments to those
reports, are available free of charge on our website as soon as reasonably practicable after they are filed with, or furnished
to, the SEC. Our Internet website is located at http://www.questdiagnostics.com. The contents of the website are not incorporated
by reference into this prospectus supplement or the accompanying prospectus. You also may request a copy of these filings, at no
cost, by writing or telephoning our Investor Relations Department at the following address:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"></P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">Quest Diagnostics Incorporated<BR>
500 Plaza Drive<BR>
Secaucus, NJ 07094<BR>
Attention: Investor Relations<BR>
(973) 520-2700</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We also incorporate by reference all
future filings we make with the SEC under Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination
of the offering made hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">PROSPECTUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>QUEST DIAGNOSTICS INCORPORATED<BR>
<BR>
Debt Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We may offer and sell, from time to time,
in one or more offerings, the debt securities we describe in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We will provide the specific terms of
these debt securities in supplements or other offering material.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><B>We urge you to read carefully this
prospectus, the accompanying prospectus supplements and other offering material, which will describe the specific terms of the
securities offered, before you make your investment decision.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We may offer and sell these debt securities
for sale directly to purchasers or through underwriters, dealers or agents to be designated at a future date. See &ldquo;Plan of
Distribution&rdquo; and any prospectus supplement for a description of the manner in which we will offer and sell the debt securities
covered by this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><B>Investing in our debt securities involves
risks that are described in the &ldquo;Risk Factors&rdquo; section of our periodic reports filed with the Securities and Exchange
Commission or in the applicable prospectus supplement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The relevant prospectus supplement will
contain information, if applicable, as to whether the debt securities offered thereby will be listed for trading on any securities
exchange or other market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><B>Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy
of this prospectus. Any representation to the contrary is a criminal offense..</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">The date of this prospectus is June 14,
2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 50; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right">Page</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.3in; width: 88%"><A HREF="#AboutThisProspectus2">ABOUT THIS PROSPECTUS</A></TD>    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; width: 12%">ii</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.3in"><A HREF="#WhereYouCanFind2">WHERE YOU CAN FIND MORE INFORMATION</A></TD>    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">1</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.5in; padding-right: 0.3in; text-indent: -0.5in"><A HREF="#CautionaryStatement2">CAUTIONARY STATEMENT FOR PURPOSES OF THE &ldquo;SAFE HARBOR&rdquo; PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995</A></TD>    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">2</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.3in"><A HREF="#ProspectusSummary2">PROSPECTUS SUMMARY</A></TD>    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">5</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.3in"><A HREF="#RiskFactors2">RISK FACTORS</A></TD>    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">6</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.3in"><A HREF="#UseofProceeds2">USE OF PROCEEDS</A></TD>    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">7</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.3in"><A HREF="#SecuritiesWeMayIssue">SECURITIES WE MAY ISSUE</A></TD>    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">8</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.3in"><A HREF="#DescriptionofSenior2">DESCRIPTION OF SENIOR DEBT SECURITIES</A></TD>    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">9</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.3in"><A HREF="#PlanofDistribution2">PLAN OF DISTRIBUTION</A></TD>    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">10</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 0.3in"><A HREF="#Validity2">VALIDITY OF THE SECURITIES</A></TD>    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">11</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 0.3in"><A HREF="#Experts2">EXPERTS</A></TD>    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right">11</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 51; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B><A NAME="AboutThisProspectus2" TITLE="AboutThisProspectus2"></A>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The information contained in this prospectus
is not complete and may be changed. We have not authorized anyone to provide you with any information or to make any representation
not contained in or incorporated by reference into this prospectus or any prospectus supplement or included in any free writing
prospectus that we may file with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;), in connection with any offering
of the debt securities described in this prospectus. We do not take any responsibility for, and can provide no assurances as to,
the reliability of any information that others may provide you. We are not making an offer of any securities in any jurisdiction
where the offer is not permitted. You should not assume that the information in this prospectus, any prospectus supplement or any
document incorporated by reference is accurate as of any date other than the date of the document in which such information is
contained or such other date referred to in such document, regardless of the time of any sale or issuance of a security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">This prospectus is part of a registration
statement that we filed with the SEC using a &ldquo;shelf&rdquo; registration process. This prospectus provides you with a limited
description of the securities we may offer. Each time we sell or issue securities, we will provide a prospectus supplement and,
if applicable, a pricing supplement, that will contain specific information about the terms of that specific offering of securities
and the specific manner in which they may be offered. The prospectus supplement and any applicable pricing supplement may also
add to, update or change any of the information contained in this prospectus. The prospectus supplement and any applicable pricing
supplement may also contain information about any material U.S. federal income tax considerations relating to the securities described
in the prospectus supplement. You should read both this prospectus, the applicable prospectus supplement and any applicable pricing
supplement, together with the additional information, which is incorporated by reference in this prospectus, described under &ldquo;Where
You Can Find More Information.&rdquo; You should read the entire prospectus and the applicable prospectus supplement, including
the information incorporated by reference, before making an investment decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">As used in this prospectus, the terms
&ldquo;Quest Diagnostics,&rdquo; &ldquo;we,&rdquo; &ldquo;us&rdquo; and &ldquo;our&rdquo; refer to Quest Diagnostics Incorporated
and its consolidated subsidiaries, unless the context clearly indicates otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">This prospectus contains summaries of
certain provisions contained in some of the documents described herein, but reference is made to the actual document for complete
information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred
to herein have been filed or will be filed or incorporated by reference as exhibits to the registration statement of which this
prospectus is a part, and you may obtain copies of those documents as described below under &ldquo;Where You Can Find More Information.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The registration statement that contains
this prospectus (including the exhibits to the registration statement) contains additional information about us and the securities
offered under this prospectus. That registration statement can be read at the SEC website (<FONT STYLE="font-size: 12pt">www.sec.gov</FONT>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B><A NAME="WhereYouCanFind2" TITLE="WhereYouCanFind2"></A>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We file annual, quarterly and current
reports, proxy statements and other information with the SEC. Our filings are available to the public on the Internet, through
a database maintained by the SEC at http://www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The SEC allows us to incorporate by reference
into this document the information we filed with the SEC. This means that we can disclose important business, financial and other
information to you by referring you to other documents separately filed with the SEC. All information incorporated by reference
is part of this document, unless and until that information is updated and superseded by the information contained in this document,
any prospectus supplement or in any document that we file with the SEC after the date hereof that is incorporated herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We incorporate by reference the following
documents filed with the SEC:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">1.</TD><TD>Our current reports on Form 8-K, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1022079/000102207919000032/dgx0218198-k.htm">February 22, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1022079/000094787119000180/ss127936_8k.htm">March 4, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1022079/000094787119000202/ss128814_8k.htm">March 12, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1022079/000102207919000098/dgx0401198-k.htm">April 1, 2019</A> (as
amended by our current report on Form 8-K/A filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1022079/000102207919000145/dgx0401198-ka.htm">May 17, 2019</A>), <A HREF="http://www.sec.gov/Archives/edgar/data/1022079/000102207919000144/dgx0513198-k.htm">May 17, 2019</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1022079/000094787119000415/ss138857_8k.htm">June 3, 2019</A>;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.</TD><TD>Our proxy statement on Schedule 14A filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1022079/000093041319001130/c93233_def14a.htm">April 3, 2019</A>;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">3.</TD><TD>Our annual report on Form 10-K for the fiscal year ended <A HREF="http://www.sec.gov/Archives/edgar/data/1022079/000102207919000030/dgx1231201810-k.htm">December 31, 2018</A>; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">4.</TD><TD>Our quarterly report on Form 10-Q for the quarter ended <A HREF="http://www.sec.gov/Archives/edgar/data/1022079/000102207919000118/dgx0331201910-q.htm">March 31, 2019</A>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We also incorporate by reference all
future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Securities and Exchange Act of 1934 prior to
the completion of the offering of the particular securities covered by a prospectus supplement or term sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Our filings with the SEC, including our
annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports, are available
free of charge on our website as soon as reasonably practicable after they are filed with, or furnished to, the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">You also may request a copy of these
filings, at no cost, by writing or telephoning our Investor Relations Department at the following address:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">Quest Diagnostics Incorporated<BR>
500 Plaza Drive<BR>
Secaucus, New Jersey 07094<BR>
Attention: Investor Relations<BR>
(973) 520-2700</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Our internet website is located at http://www.questdiagnostics.com.
The contents of the website are not incorporated by reference into this prospectus.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 53; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><A NAME="CautionaryStatement2" TITLE="CautionaryStatement2"></A><B>CAUTIONARY STATEMENT FOR PURPOSES
OF THE &ldquo;SAFE HARBOR&rdquo; PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Some statements and disclosures in this
prospectus, any accompanying prospectus supplement or other offering material and the documents incorporated herein or therein
by reference are forward-looking statements. Forward-looking statements include all statements that do not relate solely to historical
or current facts and can be identified by the use of words such as &ldquo;may,&rdquo; &ldquo;believe,&rdquo; &ldquo;will,&rdquo;
&ldquo;expect,&rdquo; &ldquo;project,&rdquo; &ldquo;estimate,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;plan&rdquo; or &ldquo;continue.&rdquo;
These forward-looking statements are based on our current plans and expectations and are subject to a number of risks and uncertainties
that could cause our plans and expectations, including actual results, to differ materially from the forward-looking statements.
The Private Securities Litigation Reform Act of 1995, or the Litigation Reform Act, provides a &ldquo;safe harbor&rdquo; for forward-looking
statements to encourage companies to provide prospective information about their companies without fear of litigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We would like to take advantage of the
&ldquo;safe harbor&rdquo; provisions of the Litigation Reform Act in connection with the forward-looking statements included or
incorporated by reference in this document. Investors are cautioned not to unduly rely on such forward-looking statements when
evaluating the information presented or incorporated by reference in this document. The following important factors could cause
our actual financial results to differ materially from those projected, forecasted or estimated by us in forward-looking statements:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>Heightened competition from commercial clinical testing companies, hospitals, physicians and others.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>Increased pricing pressure from customers, including payers and patients.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>A decline in economic conditions.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD>Impact of changes in payment mix, including increased patient financial responsibility and any shift from fee-for-service to
discounted, capitated or bundled fee arrangements.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD>Adverse actions by government or other third-party payers, including healthcare reform that focuses on reducing healthcare
costs but does not recognize the value and importance to healthcare of clinical testing or innovative solutions, unilateral reduction
of fee schedules payable to us, unilateral recoupment of amounts allegedly owed and competitive bidding.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(f)</TD><TD>The impact upon our testing volume and collected revenue or general or administrative expenses resulting from compliance with
policies and requirements imposed by Medicare, Medicaid and other third-party payers. These include:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(1)</TD><TD>the requirements of government and other payers to provide diagnosis codes and other information for many tests;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(2)</TD><TD>inability to obtain from patients a valid advance consent form for tests that cannot be billed without prior receipt of the
form;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(3)</TD><TD>the impact of additional or expanded limited coverage policies and limits on the allowable number of test units or ordering
frequency of same; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(4)</TD><TD>the impact of increased prior authorization programs.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(g)</TD><TD>Adverse results from pending or future government investigations, lawsuits or private actions. These include, in particular,
monetary damages, loss or suspension of licenses, and/or suspension or exclusion from the Medicare and Medicaid programs and/or
criminal penalties.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(h)</TD><TD>Failure to efficiently integrate acquired businesses and to manage the costs related to any such integration, or to retain
key technical, professional or management personnel.</TD></TR></TABLE>

<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD>Denial, suspension or revocation of Clinical Laboratory Improvement Act (&ldquo;CLIA&rdquo;) certification or other licenses
for any of our clinical laboratories under the CLIA standards, revocation or suspension of the right to bill the Medicare and Medicaid
programs or other adverse regulatory actions by federal, state and local agencies.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(j)</TD><TD>Changes in and complexity of federal, state or local laws or regulations, including changes that result in new or increased
federal or state regulation of commercial clinical laboratories, tests developed by commercial clinical laboratories or other products
or services that we offer or activities in which we are engaged, including regulation by the U.S. Food and Drug Administration.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(k)</TD><TD>Inability to achieve expected benefits from our acquisitions of other businesses.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(l)</TD><TD>Inability to achieve additional benefits from our business performance tools and efficiency initiatives.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(m)</TD><TD>Adverse publicity and news coverage about the diagnostic information services industry or us.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(n)</TD><TD>Failure of the Company to maintain, defend and secure its financial, accounting, technology, customer data and other operational
systems from cyberattacks, information technology system outages, telecommunications failures, malicious human acts and failure
of the systems of third parties upon which the Company relies.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(o)</TD><TD>Development of technologies that substantially alter the practice of clinical testing, including technology changes that lead
to the development of more convenient or cost-effective testing, or testing to be performed outside of a commercial clinical laboratory,
such as (1) point-of-care testing that can be performed by physicians in their offices, (2) advanced testing that can be performed
by hospitals in their own laboratories or (3) home testing that can be carried out without requiring the services of clinical laboratories.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(p)</TD><TD>Negative developments regarding intellectual property and other property rights that could prevent, limit or interfere with
our ability to develop, perform or sell our tests or operate our business. These include:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(1)</TD><TD>Issuance of patents or other property rights to our competitors or others; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(2)</TD><TD>Inability to obtain or maintain adequate patent or other proprietary rights for our products and services or to successfully
enforce our proprietary rights.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(q)</TD><TD>Development of tests by our competitors or others which we may not be able to license, or usage of our technology or similar
technologies or our trade secrets or other intellectual property by competitors, any of which could negatively affect our competitive
position.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(r)</TD><TD>Regulatory delay or inability to commercialize newly developed or licensed tests or technologies or to obtain appropriate reimbursements
for such tests.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(s)</TD><TD>The complexity of billing and revenue recognition for clinical laboratory testing.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(t)</TD><TD>Changes in interest rates and changes in our credit ratings from S&amp;P Global, Moody&rsquo;s Investor Services or Fitch Ratings
causing an unfavorable impact on our cost of and access to capital.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(u)</TD><TD>Inability to hire or retain qualified or key senior management personnel.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD>Terrorist and other criminal activities, hurricanes, earthquakes or other natural disasters, and health pandemics, which could
affect our customers, transportation or systems, or our facilities, and for which insurance may not adequately reimburse us.</TD></TR></TABLE>

<!-- Field: Page; Sequence: 55 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(w)</TD><TD>Difficulties and uncertainties in the discovery, development, regulatory environment and/or marketing of new services or solutions
or new uses of existing tests.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(x)</TD><TD>Failure to adapt to changes in the healthcare system (including the medical laboratory testing market) and healthcare delivery,
including those stemming from the Affordable Care Act (or its repeal, amendment or replacement), Protecting Access to Medicare
Act, trends in utilization of the healthcare system and increased patient financial responsibility for services.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(y)</TD><TD>Results and consequences of governmental inquiries.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(z)</TD><TD>Difficulty in implementing, or lack of success with, our strategic plan.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(aa)</TD><TD>The impact of informatics on our industry and the ability of our Company to adapt to that impact.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(bb)</TD><TD>Failure to adequately operationalize appropriate controls around use of our data, including risk of non-compliance with privacy
law requirements.</TD></TR></TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B>&nbsp;</P>

<!-- Field: Page; Sequence: 56 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B><A NAME="ProspectusSummary2" TITLE="ProspectusSummary2"></A>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><I>This summary highlights some of the
information incorporated by reference into this prospectus. Because this is only a summary, it does not contain all of the information
that may be important to you. You should carefully read this prospectus, the applicable prospectus supplement, and any other offering
material including the documents incorporated by reference, which are described under &ldquo;Where You Can Find More Information.&rdquo;
You should also carefully consider, among other things, the matters discussed in the section entitled &ldquo;Risk Factors.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>The Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Quest Diagnostics empowers people to
take action to improve health outcomes. We use our extensive database of clinical lab results to derive diagnostic insights that
reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Our diagnostic information
services business provides information and insights based on the industry-leading menu of routine, non-routine and advanced clinical
testing and anatomic pathology testing, and other diagnostic information services. We provide services to a broad range of customers,
including patients, clinicians, hospitals, independent delivery networks, health plans, employers and accountable care organizations.
We offer the broadest access in the United States to diagnostic information services through our nationwide network of laboratories,
patient service centers and phlebotomists in physician offices and our connectivity resources, including call centers and mobile
paramedics, nurses and other health and wellness professionals. We are the world&rsquo;s leading provider of diagnostic information
services. We provide interpretive consultation with one of the largest medical and scientific staffs in the industry. Our diagnostic
information services business makes up approximately 95% of our consolidated net revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">In our Diagnostic Solutions businesses,
which represents the balance of our consolidated net revenues, we offer a variety of solutions for life insurers and healthcare
organizations and clinicians. We are the leading provider of risk assessment services for the life insurance industry. In addition,
we offer healthcare organizations and clinicians robust information technology solutions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Quest Diagnostics was incorporated in
Delaware in 1990; its predecessor companies date back to 1967. We conduct business through our headquarters in Secaucus, New Jersey,
and our laboratories, patient service centers, offices and other facilities around the United States and in selected locations
outside the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">During 2018, we generated net revenues
of $7.5 billion and processed approximately 168 million test requisitions through our extensive laboratory network.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Our principal executive offices are located
at 500 Plaza Drive, Secaucus, New Jersey 07094, telephone number: (973) 520-2700.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 57 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B><A NAME="RiskFactors2" TITLE="RiskFactors2"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Our business is subject to significant
risks. You should carefully consider the risks and uncertainties set forth in Part I, Item 1A. under the heading &ldquo;Risk Factors&rdquo;
included in our annual report on Form 10-K and in &ldquo;Item 1A. Risk Factors&rdquo; in any quarterly report on Form 10-Q, which
are incorporated by reference in this prospectus. Additional risk factors that you should carefully consider will also be included
in a prospectus supplement relating to an offering of our securities as well as the other documents filed with the SEC that are
incorporated by reference herein or therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The risks and uncertainties described
in any accompanying prospectus supplement as well as the documents incorporated by reference herein or therein are not the only
ones facing us. Additional risks and uncertainties that we do not presently know about or that we currently believe are not material
may also adversely affect our business. If any of the risks and uncertainties described in this prospectus, any accompanying prospectus
supplement or the documents incorporated by reference herein or therein actually occur, our business, financial condition, results
of operations and prospects could be adversely affected in a material way. The occurrence of any of these risks may cause you to
lose all or part of your investment in the offered securities.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"></P>

<!-- Field: Page; Sequence: 58 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B><A NAME="UseofProceeds2" TITLE="UseofProceeds2"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Except as may be described otherwise
in a prospectus supplement or other offering material, we will add the net proceeds from the sale of the securities under this
prospectus to our general funds and will use them for general corporate purposes, which may include, among other things, funding
acquisitions, capital expenditures, or reducing or refinancing indebtedness.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"></P>

<!-- Field: Page; Sequence: 59 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><A NAME="SecuritiesWeMayIssue" TITLE="SecuritiesWeMayIssue"></A><B>SECURITIES WE MAY ISSUE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">This prospectus is part of a registration
statement that we filed with the SEC utilizing a &ldquo;shelf&rdquo; registration process. Under this shelf process, we may sell
our debt securities in one or more offerings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The terms of the debt securities will
be determined at the time of offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Prospectus Supplement or Pricing Supplement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">This prospectus provides you with a general
description of the debt securities we may offer. Each time we sell debt securities, we will provide a prospectus supplement or
pricing supplement that will contain specific information about the terms of that offering. The prospectus supplement or pricing
supplement may also add to or change information contained in this prospectus. If so, the prospectus supplement or pricing supplement
should be read as superseding this prospectus. You should read both this prospectus and any prospectus supplement or pricing supplement
together with additional information described under the heading &ldquo;Where You Can Find More Information.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The prospectus supplement or pricing
supplement to be provided with this prospectus will describe the terms of any debt securities that we offer and any initial offering
price to the public in that offering, the purchase price and net proceeds that we will receive and the other specific terms related
to our offering of the debt securities. For more details on the terms of the debt securities, you should read the exhibits filed
with or incorporated by reference in our registration statement, of which this prospectus is a part.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 60 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><A NAME="DescriptionofSenior2" TITLE="DescriptionofSenior2"></A><B>DESCRIPTION OF SENIOR DEBT SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We may issue senior debt securities from
time to time in one or more distinct series.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">As required by U.S. federal law for all
bonds and notes of companies that are publicly offered, the senior debt securities will be governed by a document called an &ldquo;indenture.&rdquo;
An indenture is a contract between us and a financial institution, in this case, The Bank of New York Mellon formerly known as
The Bank of New York, acting as trustee on your behalf, or other trustee we may select. The indenture will be subject to and governed
by the Trust Indenture Act of 1939.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We have filed the indenture as an exhibit
to our Securities Act filings and Exchange Act reports that we have filed with the SEC. See &ldquo;Where You Can Find More Information&rdquo;
for information on how to obtain a copy of the indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The senior debt securities will be issued
under an indenture dated as of June 27, 2001 as supplemented by a first supplemental indenture, dated as of June 27, 2001, each
among Quest Diagnostics, as issuer, the Initial Subsidiary Guarantors (as defined therein), as guarantors, and The Bank of New
York, as trustee, as further supplemented by a second supplemental indenture, dated as of November 26, 2001, among Quest Diagnostics,
the Subsidiary Guarantors (as defined therein) and The Bank of New York, as further supplemented by a third supplemental indenture,
dated as of April 4, 2002, among Quest Diagnostics, the Additional Subsidiary Guarantors (as defined therein) and The Bank of New
York, as further supplemented by a fourth supplemental indenture, dated as of March 19, 2003, among Quest Diagnostics, the Additional
Subsidiary Guarantor (as defined therein) and The Bank of New York, as further supplemented by a fifth supplemental indenture,
dated as of April 16, 2004, among Quest Diagnostics, the Additional Subsidiary Guarantor (as defined therein) and The Bank of New
York, as further supplemented by a sixth supplemental indenture, dated as of October 31, 2005, among Quest Diagnostics, the Subsidiary
Guarantors (as defined therein) and The Bank of New York, as further supplemented by a seventh supplemental indenture, dated as
of November 21, 2005, among Quest Diagnostics, the Additional Subsidiary Guarantors (as defined therein) and The Bank of New York,
as further supplemented by an eighth supplemental indenture, dated as of July 31, 2006, among Quest Diagnostics, the Additional
Subsidiary Guarantors (as defined therein) and The Bank of New York, as further supplemented by the ninth supplemental indenture
dated, September 30, 2006, among Quest Diagnostics, the Additional Subsidiary Guarantors (as defined therein) and The Bank of New
York, as further supplemented by the tenth supplemental indenture, dated June 22, 2007, among Quest Diagnostics, the Subsidiary
Guarantors (as defined therein) and The Bank of New York, as further supplemented by the eleventh supplemental indenture, dated
June 22, 2007, among Quest Diagnostics, the Additional Subsidiary Guarantors (as defined therein) and The Bank of New York, as
further supplemented by the twelfth supplemental indenture, dated June 25, 2007, among Quest Diagnostics, the Additional Subsidiary
Guarantors (as defined therein) and The Bank of New York, as further supplemented by the thirteenth supplemental indenture, dated
November 17, 2009, among Quest Diagnostics, the Subsidiary Guarantors (as defined therein) and The Bank of New York Mellon, as
further supplemented by the fourteenth supplemental indenture, dated March 24, 2011, among Quest Diagnostics, the Subsidiary Guarantors
(as defined therein) and The Bank of New York Mellon, as further supplemented by the fifteenth supplemental indenture, dated November
30, 2011, among Quest Diagnostics, the Additional Subsidiary Guarantors (as defined therein) and The Bank of New York Mellon, as
further supplemented by the sixteenth supplemental indenture, dated March 17, 2014, among Quest Diagnostics and The Bank of New
York Mellon, as further supplemented by the seventeenth supplemental indenture, dated March 10, 2015, among Quest Diagnostics and
The Bank of New York Mellon, as further supplemented by the eighteenth supplemental indenture, dated as of May 26, 2016, among
Quest Diagnostics and The Bank of New York Mellon, and as further supplemented by the nineteenth supplemental indenture, dated
as of March 12, 2019, among Quest Diagnostics and The Bank of New York Mellon (collectively, as so supplemented, the &ldquo;Indenture&rdquo;).
The Indenture for the senior debt securities may also be modified by future supplemental indentures. The terms of the senior debt
securities include those stated in the Indenture and those made part of the Indenture by reference to the Trust Indenture Act of
1939. A copy of the Indenture is available for inspection at the office of the trustee.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"></P>

<!-- Field: Page; Sequence: 61 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><A NAME="PlanofDistribution2" TITLE="PlanofDistribution2"></A><B>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We may sell the debt securities to or
through agents, dealers or underwriters or directly to one or more purchasers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>By Agents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We may use agents to sell the debt securities.
Unless otherwise stated in a prospectus supplement or other offering material, the agents will agree to use their reasonable best
efforts to solicit purchases for the period of their appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>By Underwriters or Dealers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We may sell the debt securities to underwriters.
The underwriters may resell the debt securities in one or more transactions, including negotiated transactions, at a fixed public
offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the debt securities
will be subject to certain conditions. Each underwriter will be obligated to purchase all the debt securities allocated to it under
the underwriting agreement. The underwriters may change any initial public offering price and any discounts or concessions they
give to dealers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">A prospectus supplement and/or any additional
offering material will state the name of any underwriter and the amount of compensation, underwriting discounts, commissions, or
concessions paid or allowed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Direct Sales</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We may sell debt securities directly
to investors. In this case, no underwriters, dealers or agents would be involved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">As one of the means of direct issuance
of debt securities, we may utilize the services of any available electronic auction system to conduct an electronic &ldquo;dutch
auction&rdquo; of the offered securities among potential purchasers who are eligible to participate in the auction of those offered
debt securities, if so described in the prospectus supplement or pricing supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>General Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We may have agreements with the underwriters,
dealers and agents to indemnify them against certain civil liabilities, including liabilities under the Securities Act, or to contribute
to payments they may be required to make.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Underwriters, dealers and agents may
engage in transactions with, or perform services for, us or our subsidiaries in the ordinary course of their business.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"></P>

<!-- Field: Page; Sequence: 62 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B><A NAME="Validity2" TITLE="Validity2"></A>VALIDITY OF THE SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The validity of any securities issued
hereunder will be passed upon for us by Shearman &amp; Sterling LLP, New York, New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B><A NAME="Experts2" TITLE="Experts2"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The financial statements and management&rsquo;s
assessment of the effectiveness of internal control over financial reporting (which is included in the Report of Management on
Internal Control over Financial Reporting) incorporated in this Prospectus by reference to the Annual Report on Form 10-K for the
year ended December 31, 2018, have been so incorporated in reliance on the report of PricewaterhouseCoopers LLP, an independent
registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 63 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 3.5pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">$550,000,000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="image_002.jpg" ALT="Description: C:\Users\dy23967\Desktop\Quest-logo[2].jpg" STYLE="height: 77px; width: 217px"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">Quest Diagnostics Incorporated</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 24pt; text-align: center">2.800% Senior Notes due 2031</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.4in; text-align: center"><B>PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>Goldman Sachs &amp; Co. LLC</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>J.P. Morgan</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>Mizuho Securities</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>Morgan Stanley</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>Wells Fargo Securities</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>Credit
Agricole CIB</B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>MUFG</B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>Fifth
Third Securities</B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>PNC
Capital Markets LLC</B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>BNY
Mellon Capital Markets, LLC</B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>BofA
Securities</B></FONT></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>KeyBanc
Capital Markets</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0.25in"><B>May 11, 2020</B></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 3.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->











<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in; text-indent: -0.5in"></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" "L 6H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"ZK\1@I:/2K;?_TUEX'X"N<N/%VNW#$F^>,>D:A13E7@B742/7:*\?A\6:[
MX8:A(^.S@,*['PSXX75)DL]118;EN$=?NN?3V-$:T9.P*HF=A124M;%A1110
M 4E%<9X^\22:?"FG6;E)YEW2..J)Z#W-3*7*KL3=E<T]7\;:5I,C1&1KB=>J
M1<X^IZ5BCXGV^_G3I=OKY@S65X4\$_VQ +W4&>.U8_(B\-)[Y["NN;P+H31;
M/L97_:#G-9)U):HS3F]271O%^EZRXBAE,4YZ12C!/T[&MS->3^*O"4OAYEN;
M:1Y+1FP'/WHV[9_QKL/ _B)]9T][>Z;==VV 6_OKV/UJH3=^66XXR=[2.HHK
M%UKQ7I^@W207GG;W3>-B9&,X_I6I9W4=]9PW,.?+E0.N1@X-:*2O8NZV)J6L
MS6M=M-!@CEO?,VR-L78N><9J31]8MM;L?M5IO\K>4^<8.11=7L%U>Q?I*HZK
MK5EHT EOIQ&#]U>K-]!7._\ "RM+\S'D76S^]M'\LTG.*W8.26YV-)5'2]8L
MM9@\ZQG611PPZ,OU%6YYX[:%YII%CC099F. !3OU'<?2UR5Q\1M(BE*1K<3*
M/XU3 _6M'2_%^DZM(L4%QLF;I'*-I/T]:2G%NUR5)%W4];L-'$9OYQ")20F0
M3G'6IK&_M]2M%N;.020OG:P'7'%<5\4/]5IO^\_\A3O!GBK3;+2K33+B1XYM
MS#<R_)DDD<U'M+3Y6+G]ZS.\HI!S2UJ6%%%% !1110 4444 %%%% !1110 4
M444 %<#\0M4+W,&FQM\J#S91ZG^$?UKO:\=U>X?4_$UVZ99I)S&@^AV@?I7/
MB)-0LNI%1Z&UX0T/^U+OSIE_T:$_-_MMV%>D    < 52T?34TK2X;5,91<N?
M5NYJ>[NHK*TEN9VVQ1*68TZ--4X^8XJR*>MZW;:'9&>X.YVXCC!Y<UY=JVK7
MFN7)FO)/E!^2,?=0>P_K2ZMJD^MZB]U/D#I&G9%["H8XJXZ^(YG9;&<I<Q"L
M-.\FKBQ4_P GVKC=07*9YAJ,QE&#*2&!R".QK2:&H7BJHU Y3U;0;XZEHEI=
M-]]T^?\ WAP?U%6KQG2RF>(XD5"5^H%9'@Q"GABVSW+$?3<:V;@@6TI/0(?Y
M5[4'>"9LMB*PNTO[""ZC^Y,@<>V15FN5^'EY]I\-^43DP2L@^AY'\ZZJG%W5
MP3NKB5X[XOD:Y\77H<])!&/8  5[%7E/C_3GL_$;W&"([I0ZM_M#@C^7YUG7
M^$BKL>HVL"6UK##& $C0* /0"IJQ?"^MQ:WH\4BL//C4),G<,._T-:&H7<EE
M9O/';R7!3DQQD;B/:M$U:Y:>ER#Q!;)>:!?12#*F%C]"!D?RKSCX>3-'XHC4
M'B6)U;\L_P!*UM9^(4%YI5S:VUK/'-*A3<^,+GK5?X:Z:TFHSW[*1'"GEJ?5
MCU_3^=8R:E-6,FTY*Q'\3/\ D.VW_7M_[,:[OPW_ ,BWIW_7NG\JX7XF#_B>
MVO\ U[?^S&NW\,2+)X9TYD.1Y"C\1Q3A_$D./QLY_P")W_(*LO\ KN?_ $$U
M8^'LBP^$I)'.$2:1F/L,54^)TB_V?8QY&\RLP'L!_P#7IW@Z)IO %[&GWW,R
MCZ[:/^7C] ^V<O"MQXU\58ED*I(2V?\ GG&.P_SU-=V? V@FU\D6^#C'F"0[
ML^N:\VT#3)-7U);.&Y%M*RDJS9YQVXKJ?^%=ZI_T%D_-ZB%VKVN3'76US%MY
M)_!WBXQ^862-PKXZ21G_ .L<UU7Q*GE71;6.,GRI9OGQWP,BLM_AI?R'+ZC
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MS6O24M=D596+6@5B>+<_V"P#,NZ:)25.#@N >:VZQ/%O_(#_ .V\/_HQ:);
M]AW_  BVF]EG4^HG?(_6J\CW7AR>%I;B2ZTR5Q&QE.7@8\ Y[KGUZ5T%8WBY
ME'AF\0\M(!&@]6) &/QJ6DE=":L7-06U:2S-U(R,)QY.UB-SX. <=>]27NHV
MNG1A[N98U8X7/5CZ =ZS=;!5M%#?>%[&#_WR:LZCJ26]W#;0VK7=XP+I&N!M
M7IN)/04[CN%MX@T^[N%@CG*RO]U9$*%OID<UH,ZHA=R%51DDG %<OXCN-0FT
M2X-UI(3RU\Q)4G5C&P.0?7\JMZ^QN(M)M93B"[N%6;MN&TMM^A(%+F%<L?\
M"4:7NXG8IG'FB-MG_?6,5H0WMO<3/%#*KNBJY"G/#=#GWQ4HC18Q&J*$ P%
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M#2[N]O8KS6)(SY)W0VT6=B-_>)/WC6U24K=Q6,W5[.:[FTYH5!$%TLKY.,*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#T17AI9@  34T *@    @ ! $[  (
M   .   (2H=I  0    !   (6)R=  $    <   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UA<G1I;B!(
M=6=H97,   60 P "    %   $*:0!  "    %   $+J2D0 "     S(S  "2
MD@ "     S(S  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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MRU<5"F^5:LB4TM$>N7?BS0+%REUK%G&PZKYP)'X"F6_C+PY=N%@UJR9CT!F
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MI?V=XGT)2<)>O+;,/7*AE_5?UK>KU$[LVN9OB#6(M T"[U.<;EMX]P7/WFZ
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M/WS%2AQG#<D$<&O77O8?L<MQ#(DR1(6/EL#T&<5%!J O=)6\L_+=WA$BHT@
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M(-#A8&:ZOIQ_=+JH/Y"N_HK)T:;W1')'L96D^&M(T,?\2VQCB?&#(1N<_P#
MCS6K116BBHJR+V"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
(% !1110!_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
